



Cochrane
Library

Cochrane Database of Systematic Reviews

Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*) (Review)

Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, Nicholson MR, Imdad A

Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, Nicholson MR, Imdad A.
Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*).
Cochrane Database of Systematic Reviews 2023, Issue 4. Art. No.: CD013871.
DOI: [10.1002/14651858.CD013871.pub2](https://doi.org/10.1002/14651858.CD013871.pub2).

www.cochranelibrary.com

Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*) (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	6
OBJECTIVES	7
METHODS	7
RESULTS	10
Figure 1.	11
Figure 2.	14
Figure 3.	15
DISCUSSION	16
AUTHORS' CONCLUSIONS	18
ACKNOWLEDGEMENTS	18
REFERENCES	19
CHARACTERISTICS OF STUDIES	26
RISK OF BIAS	57
DATA AND ANALYSES	60
Analysis 1.1. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 1: Resolution of rCDI: intention-to-treat analysis	61
Analysis 1.2. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 2: Resolution of rCDI: sensitivity analysis: fixed-effect model	62
Analysis 1.3. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 3: Resolution of rCDI: sensitivity analysis: as-available analysis	62
Analysis 1.4. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 4: Resolution of rCDI: sensitivity analysis: excluding immunocompromised participants ...	63
Analysis 1.5. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 5: Serious adverse events: intention-to-treat analysis	63
Analysis 1.6. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 6: Serious adverse events: sensitivity analysis: fixed-effect model	64
Analysis 1.7. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 7: Serious adverse events: sensitivity analysis: as-available analysis	64
Analysis 1.8. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 8: Serious adverse events: sensitivity analysis: excluding immunocompromised participants	65
Analysis 1.9. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 9: All-cause mortality: intention-to-treat analysis	65
Analysis 1.10. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 10: All-cause mortality: sensitivity analysis: fixed-effect model	66
Analysis 1.11. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 11: All-cause mortality: sensitivity analysis: as-available analysis	66
Analysis 1.12. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 12: All-cause mortality: sensitivity analysis: excluding immunocompromised participants ..	67
Analysis 1.13. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent <i>Clostridioides</i> <i>difficile</i> infections (rCDI), Outcome 13: Withdrawals	67
ADDITIONAL TABLES	68
APPENDICES	71
HISTORY	75
CONTRIBUTIONS OF AUTHORS	75
DECLARATIONS OF INTEREST	76
SOURCES OF SUPPORT	76
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	76
INDEX TERMS	77

[Intervention Review]

Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*)

Nathan Zev Minkoff¹, Scheherzade Aslam², Melissa Medina³, Emily E Tanner-Smith⁴, Joseph P Zackular⁵, Sari Acra⁶, Maribeth R Nicholson⁶, Amer Imdad⁷

¹Pediatric Gastroenterology, Hepatology and Nutrition, Valley Children's Hospital, Madera, California, USA. ²Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Nebraska Medical Center, Omaha, Nebraska, USA. ³Department of Public Health and Preventative Medicine, SUNY Upstate Medical University, Syracuse, New York, USA. ⁴Counseling Psychology and Human Services, University of Oregon, Eugene, Oregon, USA. ⁵Department of Pathology and Laboratory Medicine, University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. ⁶Department of Pediatrics, D. Brent Polk Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. ⁷Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, SUNY Upstate Medical University, Syracuse, New York, USA

Contact: Amer Imdad, aamer08@gmail.com.

Editorial group: Cochrane Gut Group.

Publication status and date: New, published in Issue 4, 2023.

Citation: Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, Nicholson MR, Imdad A. Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*). *Cochrane Database of Systematic Reviews* 2023, Issue 4. Art. No.: CD013871. DOI: [10.1002/14651858.CD013871.pub2](https://doi.org/10.1002/14651858.CD013871.pub2).

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Clostridioides difficile (formerly known as *Clostridium difficile*) is a bacterium that can cause potentially life-threatening diarrheal illness in individuals with an unhealthy mixture of gut bacteria, known as dysbiosis, and can cause recurrent infections in nearly a third of infected individuals. The traditional treatment of recurrent *C difficile* infection (rCDI) includes antibiotics, which may further exacerbate dysbiosis. There is growing interest in correcting the underlying dysbiosis in rCDI using of fecal microbiota transplantation (FMT); and there is a need to establish the benefits and harms of FMT for the treatment of rCDI based on data from randomized controlled trials.

Objectives

To evaluate the benefits and harms of donor-based fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* infection in immunocompetent people.

Search methods

We used standard, extensive Cochrane search methods. The latest search date was 31 March 2022.

Selection criteria

We considered randomized trials of adults or children with rCDI for inclusion. Eligible interventions must have met the definition of FMT, which is the administration of fecal material containing distal gut microbiota from a healthy donor to the gastrointestinal tract of a person with rCDI. The comparison group included participants who did not receive FMT and were given placebo, autologous FMT, no intervention, or antibiotics with activity against *C difficile*.

Data collection and analysis

We used standard Cochrane methods. Our primary outcomes were 1. proportion of participants with resolution of rCDI and 2. serious adverse events. Our secondary outcomes were 3. treatment failure, 4. all-cause mortality, 5. withdrawal from study, 6. rate of new CDI

infection after a successful FMT, 7. any adverse event, 8. quality of life, and 9. colectomy. We used the GRADE criteria to assess certainty of evidence for each outcome.

Main results

We included six studies with 320 participants. Two studies were conducted in Denmark, and one each in the Netherlands, Canada, Italy, and the US. Four were single-center and two were multicenter studies. All studies included only adults. Five studies excluded people who were severely immunocompromised, with only one study including 10 participants who were receiving immunosuppressive therapy out of the 64 enrolled; these were similarly distributed between the FMT arm (4/24 or 17%) and comparison arms (6/40 or 15%). The route of administration was the upper gastrointestinal tract via a nasoduodenal tube in one study, two studies used enema only, two used colonoscopic only delivery, and one used either nasojejunal or colonoscopic delivery, depending on a clinical determination of whether the recipient could tolerate a colonoscopy. Five studies had at least one comparison group that received vancomycin. The risk of bias (RoB 2) assessments did not find an overall high risk of bias for any outcome.

All six studies assessed the efficacy and safety of FMT for the treatment of rCDI.

Pooled results from six studies showed that the use of FMT in immunocompetent participants with rCDI likely leads to a large increase in resolution of rCDI in the FMT group compared to control (risk ratio (RR) 1.92, 95% confidence interval (CI) 1.36 to 2.71; $P = 0.02$, $I^2 = 63%$; 6 studies, 320 participants; number needed to treat for an additional beneficial outcome (NNTB) 3; moderate-certainty evidence). Fecal microbiota transplantation probably results in a slight reduction in serious adverse events; however, the CIs around the summary estimate were wide (RR 0.73, 95% CI 0.38 to 1.41; $P = 0.24$, $I^2 = 26%$; 6 studies, 320 participants; NNTB 12; moderate-certainty evidence). Fecal microbiota transplantation may result in a reduction in all-cause mortality; however, the number of events was small, and the CIs of the summary estimate were wide (RR 0.57, 95% CI 0.22 to 1.45; $P = 0.48$, $I^2 = 0%$; 6 studies, 320 participants; NNTB 20; low-certainty evidence). None of the included studies reported colectomy rates.

Authors' conclusions

In immunocompetent adults with rCDI, FMT likely leads to a large increase in the resolution of recurrent *Clostridioides difficile* infection compared to alternative treatments such as antibiotics. There was no conclusive evidence regarding the safety of FMT for the treatment of rCDI as the number of events was small for serious adverse events and all-cause mortality. Additional data from large national registry databases might be required to assess any short-term or long-term risks with using FMT for the treatment of rCDI. Elimination of the single study that included some immunocompromised people did not alter these conclusions. Due to the low number of immunocompromised participants enrolled, conclusions cannot be drawn about the risks or benefits of FMT for rCDI in the immunocompromised population.

PLAIN LANGUAGE SUMMARY

Stool transplantation for treatment of repeated *Clostridioides difficile* infection

Review question

We reviewed the evidence about the effect of stool transplant compared to currently used treatments such as antibiotics for the treatment of recurrent *C difficile* diarrhea in adults and children.

What is *Clostridioides difficile* infection and how is it treated?

Clostridioides difficile (*C difficile*) infection is a common bacterial illness that can cause life-threatening diarrhea (runny stools). Evidence suggests that an unhealthy mixture of gut bacteria called dysbiosis may increase the risk of repeated or multiple *C difficile* infections. Changing from an unhealthy to a healthier balance of gut bacteria through treatment may protect people from becoming sick with *C difficile*, or prevent repeated infections with this bacterium. Stool administration from healthy donors to people who have had multiple infections with *C difficile*, known as fecal microbiota transplantation (FMT), is an intervention that seeks to change an unhealthy mixture of gut microbes into a healthy balance of gut microbes.

What did we want to find out?

We wanted to discover whether using FMT in people with multiple *C difficile* infections leads to a higher percentage of resolution of the infection compared to commonly used therapies such as antibiotics and whether FMT may cause harm.

What did we do?

We searched medical databases for clinical trials looking at stool transplantation compared to currently used treatments such as antibiotics for the treatment of recurrent *C difficile* diarrhea in adults and children.

What did we find?

We found six clinical trials of 320 adults that met criteria for inclusion in this review that assessed the efficacy and safety of stool transplantation for the treatment of repeated *C difficile* infection. Two studies were conducted in Denmark, and one each in the

Netherlands, Italy, Canada, and the US. The time of follow-up after the treatment with FMT ranged from eight weeks to 17 weeks. The amount of stool, route of administration, number of administrations, type of donor, and what type of treatment the comparison group received varied among the studies. Five studies excluded people who had weak immune systems (immunocompromised people); one study included people with weak immune systems and apparently normal immune systems (immunocompetent people).

Key results

Stool transplantation probably leads to a larger increase in resolution of repeated infections of *C difficile* than the other treatments studied. Other treatments included antibiotics such as vancomycin, which are commonly prescribed for this infection. These same studies looked at the rate of serious side effects and risk of death from FMT. Fecal microbiota transplantation likely leads to a small decrease in serious side effects; however, these effects were few. Fecal microbiota transplantation may decrease the risk of death in people with rCDI; however, there were few deaths in either group. Elimination of one study that included some immunocompromised people did not alter these conclusions, but, based on the low number of immunocompromised people enrolled in the included studies, conclusions could not be drawn about the benefits or harms of FMT for rCDI in the immunocompromised population at this time.

What are the limitations of the evidence?

We rated the overall certainty of the evidence using a set of criteria that takes into account the type of studies, potential flaws in how the studies were run, how similar or different reporting of the results was between studies, how studies measured the effect of the intervention, and mathematical confidence in the combined results. Based on these criteria, we judged the overall certainty of the evidence supporting stool transplants as more effective than other treatments for the resolution of repeated *C difficile* infection as moderate. The certainty of evidence for serious side effects was moderate and the certainty of evidence for deaths was low.

Study funding sources

None of the included studies was funded by a drug manufacturer or an agency that had a commercial interest in FMT.

How up to date is this evidence?

The evidence is current to 31 March 2022.

SUMMARY OF FINDINGS

Summary of findings 1. Summary of findings table - Fecal microbiota transplantation (FMT) compared to control in adults with recurrent *Clostridioides difficile* infection (rCDI)

Fecal microbiota transplantation (FMT) compared to control in adults with recurrent *Clostridioides difficile* infection (rCDI)

Patient or population: adults with recurrent *Clostridioides difficile* infection (rCDI)

Setting: inpatient and outpatient

Intervention: fecal microbiota transplantation (FMT)

Comparison: control

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with control	Risk with fecal microbiota transplantation (FMT)				
Resolution of rCDI follow-up: range 8 weeks to 17 weeks	401 per 1000	770 per 1000 (545 to 1000)	RR 1.92 (1.36 to 2.71)	320 (6 RCTs)	⊕⊕⊕⊖ Moderate ^{a,b,c}	FMT likely results in a large increase in resolution of rCDI.
Serious adverse events follow-up: range 8 weeks to 17 weeks	225 per 1000	164 per 1000 (85 to 317)	RR 0.73 (0.38 to 1.41)	320 (6 RCTs)	⊕⊕⊕⊖ Moderate ^d	FMT probably results in a slight reduction in serious adverse events; however, the CIs around the summary estimate were wide and included a possibility of increased risk of serious adverse events.
All-cause mortality follow-up: range 8 weeks to 17 weeks	96 per 1000	55 per 1000 (21 to 140)	RR 0.57 (0.22 to 1.45)	320 (6 RCTs)	⊕⊕⊖⊖ Low ^e	FMT may result in a reduction in all-cause mortality; however, the CIs around the summary estimate were wide and possible risk of increased mortality could not be ruled out.
Colectomy	0 per 1000	0 per 1000 (0 to 0)	Not estimable	(0 studies)	-	None of the included studies reported this outcome.

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432555373835069207.

^a We did not downgrade for risk of bias for this outcome. Even though two included studies in this analysis did not describe their methods of randomization in clear detail, the study groups were balanced at the start of the study. A sensitivity analysis by excluding these studies from the meta-analysis for this outcome did not change the direction or statistical significance of the summary estimate. We also acknowledge that five of the six studies were open-label. The outcome was defined with a combination of clinical symptoms and negative test in most of the studies so it is less likely that lack of blinding biased the results.

^b Even though the statistical heterogeneity based on I² values was 63% in the pooled analysis, the direction of effect was in favor of FMT in five out of six studies included in the analysis. Therefore, we did not downgrade for statistical heterogeneity.

^c Downgraded one level due to imprecision. The CIs around the summary estimate were wide and included a small to a very large increase of resolution of rCDI.

^d Downgraded one level due to imprecision. The number of events was small and the CIs around the summary estimate were wide.

^e Downgraded two levels due to imprecision. The number of events was small and the CIs around the summary estimate were very wide and included a possibility of lower or increased risk of mortality.

BACKGROUND

Description of the condition

Clostridioides difficile (formerly known as *Clostridium difficile*) is a spore-forming, gram-positive, obligate anaerobic bacillus bacterium (Lawson 2016). It is acquired via fecal-oral transmission of spores shed in the stools of infected or colonized people, which can be transmitted via contact with any surface. *C difficile* is the most frequently reported nosocomial pathogen in the US, as healthcare facilities such as hospitals, nursing homes, and childcare facilities are major sources of transmission (Leffler 2015; Red Book 2018). *C difficile* infection (CDI) is defined by the presence of diarrheal symptoms, and a stool test positive for *C difficile* toxins, detection of toxigenic *C difficile*, or colonoscopic or histopathologic findings revealing pseudomembranous colitis (Crobach 2018; McDonald 2018; Red Book 2018). Asymptomatic *C difficile* colonization is the detection of the organism without the symptoms of the disease (Crobach 2018). Asymptomatic *C difficile* colonization is especially common in children under two years of age and testing in this age group is discouraged unless other infectious and non-infectious causes of diarrhea have been excluded (McDonald 2018). The known risk factors for CDI include antimicrobial therapy, proton pump inhibitor therapy, prolonged nasogastric tube placement, gastrostomy and jejunostomy tube placement, inflammatory bowel disease, gastrointestinal tract surgery, chronic kidney disease, repeated enemas, advanced age, organ transplantation, and immunocompromised states (Crobach 2018; Davidovics 2019; McDonald 2018; Red Book 2018). Treatment with antibiotics increases the risk of CDI, as antibiotics decrease the taxonomic richness, diversity, and evenness of the intestinal microbiota community, providing a niche for *C difficile* to flourish, as toxigenic strains of *C difficile* are favored by disturbances in the ecology of intestinal microbiota (Chang 2008; Dethlefsen 2008; Fekety 1993).

First-line treatment of CDI involves antibiotics (Davidovics 2019; McDonald 2018; Leffler 2015; Red Book 2018). Once an individual has developed CDI, they are at risk for recurrent *C difficile* infections (rCDI), which occur in 20% to 30% of individuals treated with antibiotics for an initial episode of CDI and rates increase up to 60% after the second recurrence (Davidovics 2019; Kelly 2008). Recurrent *C difficile* infections may occur either from the germination of spores from prior CDI or from reinfection with a different strain of *C difficile* acquired from human or environmental contacts (Bakken 2011; Fekety 1993). The definition of rCDI is an episode that fulfills the criteria for CDI (both diarrheal symptoms and either positive laboratory testing, colonoscopic or histopathologic findings of pseudomembranous colitis [or both]) and occurs between two and eight weeks after treatment for a previous episode of CDI, provided that the symptoms of the earlier episode initially resolved (McDonald 2007; McDonald 2018). This definition excludes any repeat positive laboratory result for *C difficile* within two weeks after the last specimen that tested positive, as this likely represents a continuation of the same CDI case (McDonald 2007). Treatment failure of CDI is defined as no response after one week of treatment with appropriate antibiotics (Shannon-Lowe 2010; Vardakas 2012). One systematic review for the treatment of CDI found a treatment failure rate of 22.4% for metronidazole and 14.2% for vancomycin (Vardakas 2012).

Description of the intervention

Most current guidelines recommend further antibiotics for the treatment of a first and second recurrence of non-severe CDI (Al Momani 2018; McDonald 2018; Mullish 2018; Red Book 2018), before recommending FMT (Bakken 2011; McDonald 2018). However, this approach might be changing following a recommendation of FMT after the first recurrence of CDI in the 2021 American College of Gastroenterology guidelines (ACG Clinical Guidelines 2021). Fecal microbiota transplantation has been defined as the administration of fecal material containing distal gut microbiota from a healthy donor to a person with a disease or condition related to dysbiosis or an alteration in their normal gut microbiota (Kelly 2015). Fecal microbiota transplantation involves the selection and screening of a donor and the appropriate selection and preparation of the recipient. There is no universally agreed-upon donor screening method, but most centers perform an interview to screen for chronic disease states along with blood and stool tests to rule out a variety of infectious diseases (Woodworth 2017). Stool specimens are also commercially available from stool banks. After appropriate screening, donor stool is collected, mixed with a solvent, and sometimes filtered, then either administered on the same day or frozen for later use. The patient is usually given a laxative or undergoes a bowel lavage prior to the procedure (Cammarota 2017; Davidovics 2019). An FMT can be administered via a colonoscopy, an enema, orally ingested capsules, a gastrostomy tube, a jejunostomy tube, or a temporary nasoduodenal or nasogastric tube (Cammarota 2017; Davidovics 2019; McDonald 2018; Imdad 2018; Jiang 2018a; Kao 2017; Lee 2016). The US Food and Drug Administration (FDA) considers FMT as an investigational procedure and requires an Investigational New Drug application for any use of FMT other than treatment of rCDI, where the FDA exercises enforcement discretion (FDA 2013).

How the intervention might work

Exposure to *C difficile* spores alone, either through new inoculation or asymptomatic carriage, is thought to be insufficient to cause CDI, necessitating coexisting dysbiosis for CDI and rCDI to occur (Kociolek 2016). Dysbiosis is broadly defined as any alteration in the composition of resident commensal bacteria communities as compared to the communities found in healthy individuals. Dysbiosis leads to loss of microbial diversity and beneficial microbes, and expansion of potentially harmful microbes (Petersen 2014). Individuals with conditions correlated with dysbiosis have higher CDI rates than the general population, including those who have recently received antibiotics, people with inflammatory bowel disease, and people receiving chemotherapy (Johnsen 2018; McDonald 2018; Petersen 2014; Razik 2016). Treatment for non-severe, uncomplicated CDI and rCDI in low-risk patients includes discontinuation of antibiotics that may have caused or exacerbated dysbiosis and initiation of antibiotics with activity against *C difficile* such as vancomycin and fidaxomicin (McDonald 2018; Red Book 2018). However, antibiotics can potentiate further dysbiosis, leading to additional episodes of rCDI (Davidovics 2019; Kelly 2008; Kociolek 2016). The ideal treatment of rCDI should attempt to restore a healthy, diverse intestinal microbiota milieu that will protect against further episodes of rCDI (Kelly 2008; Kociolek 2016). While probiotics are a potential mechanism to change the host microbiome, they are not thought to be effective as monotherapy for active CDI or to prevent rCDI, and high-quality, robust evidence to support their use is lacking (ACG Clinical Guidelines 2021; Davidovics 2019; Kelly 2008; McDonald 2018). Fecal microbiota

transplantation is likely the most effective treatment for rCDI and has become part of the standard-of-care treatment algorithms for rCDI in both adults and children (ACG Clinical Guidelines 2021; Bakken 2011; Davidovics 2019; Kellermayer 2019; McDonald 2018). Fecal microbiota transplantation attempts to correct dysbiosis by altering the recipient's microbiome via the 'transplantation' of a healthy donor's microbiota (Cammarota 2017), which in the case of rCDI, can eliminate the niche that *C difficile* is able to exploit. Fecal microbiota transplantation significantly decreases dysbiosis and increases gut microbial diversity in individuals with rCDI (Kelly 2016; Khanna 2017).

While FMT has the potential to correct dysbiosis, there is concern that pathogenic micro-organisms could be introduced, causing undesirable outcomes (Alang 2015; Cammarota 2017). Serious adverse events, including mortality, septic shock, aspiration pneumonia, and toxic megacolon have been reported (Kelly 2014; Link 2016; Solari 2014). The FDA has issued a safety alert regarding the risk of serious adverse events including mortality from the transmission of multiple-drug-resistant organisms (FDA 2020a), and provided additional guidance in regard to the risk of infection from SARS-CoV-2 (strain of coronavirus that causes COVID-19 [coronavirus disease 2019]) (FDA 2020b).

Why it is important to do this review

Clostridioides difficile was associated with almost 250,000 infections and approximately 12,800 deaths in the US in 2017 alone (CDC 2019). It is the most common healthcare-associated infection and the leading cause of gastroenteritis-associated death; the cost of managing CDI was estimated at 1 billion US dollars in the US in 2017 (CDC 2019; Lessa 2015). While there is a paucity of data on the incidence of CDI from outside North America, Europe, and the Western Pacific, one meta-analysis estimated the worldwide incidence rate of healthcare facility-associated CDI rate for patients of all ages to be 2.24 per 1000 admissions per year (Balsells 2019).

Data from observational studies show that FMT might cure more than 90% of cases with rCDI (Kassam 2013; Quraishi 2017). Such high efficacy of an intervention to cure a recurrent disease is very appealing; however, these findings need to be confirmed with data from randomized controlled trials (RCTs). Data from RCTs to define the efficacy of FMT against the standard of care have recently become available (Cammarota 2015; Hota 2017; Hvas 2019; Kelly 2016; Rode 2021; van Nood 2013). Thus, there is a need to assess this evidence in a systematic review and meta-analysis. While systematic reviews have been performed on the efficacy of FMT for rCDI, most have included observational studies, and none have used Cochrane methodology while simultaneously incorporating the Cochrane RoB 2 tool and the GRADE criteria (Drekonja 2015; Hui 2019; Khan 2018; Quraishi 2017). Therefore, we conducted a comprehensive, up-to-date systematic review to assess the efficacy of donor-based FMT versus other treatments for the treatment of rCDI.

OBJECTIVES

To evaluate the benefits and harms of donor-based fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* infection in immunocompetent people.

METHODS

Criteria for considering studies for this review

Types of studies

We included RCTs assessing FMT for the treatment of rCDI. We included trials with multiple arms, as long as these included an intervention and comparison group that addressed the primary question for this review. We planned to include both cross-over and cluster-randomized trials; however, there were none that met criteria for inclusion. We excluded observational studies, case reports, and case series.

Types of participants

We included studies of participants with rCDI. We considered the definition of CDI as any person with watery or frequent (or both) stools (more than two or three loose stools per day), who simultaneously had either a positive stool test for *C difficile* or colonoscopic or histopathologic findings (or both) of pseudomembranous colitis (McDonald 2007; McDonald 2018). A case met criteria for rCDI when the person met criteria for CDI, received treatment for CDI with antibiotics known to have activity against *C difficile* (generally metronidazole, vancomycin, fidaxomicin, or a combination of these), their diarrhea initially resolved, then the diarrhea recurred with any *C difficile* test simultaneously being positive. This would theoretically occur in a period of two to eight weeks from the previously documented positive *C difficile* stool test (McDonald 2007; McDonald 2018). We considered both children and adults. We included participants in both hospital and community settings. We did not include studies that exclusively enrolled immunocompromised people. We excluded studies that relied on clinical symptoms without laboratory confirmation when defining rCDI, as one study observed that approximately 25% (29/117) of participants with presumed rCDI referred for work-up for FMT were found to have a non-CDI diagnosis, with irritable bowel syndrome and inflammatory bowel disease being the most common alternative diagnoses (Jackson 2016).

Studies differed in the number of rCDI episodes prior to offering FMT to participants. We included studies in our analysis that provided FMT for rCDI regardless of the number of recurrences, but excluded studies where the participant received FMT as treatment for their first case of CDI, as this is not the standard of care at the time of this analysis. In defining rCDI, we did not insist on studies documenting a negative microbiologic test after treatment of CDI before the development of a recurrence as a 'test of cure' in asymptomatic participants, as this is not the standard of care, and a person might carry *C difficile* without having active symptoms (Davidovics 2019; McDonald 2018).

There are areas of ambiguity regarding CDI testing based on the limitations of available testing modalities. One area of ambiguity is the differentiation between true CDI/rCDI and carriers of *C difficile* who develop frequent or watery bowel movements (or both) for another reason but test positive for *C difficile* (Crobach 2018). Another challenge is how to compare *C difficile* testing strategies used in different trials, as there are a wide variety of testing modalities available, which vary in sensitivity and specificity. There is currently no gold standard laboratory test method available, and the evidence base to optimize testing is weak (Crobach 2018; McDonald 2018; Red Book 2018). Therefore, we accepted

any form of positive stool testing for documentation of CDI and rCDI. A third area of ambiguity concerns differentiating between the 'recurrence' of the same *C difficile* infection from a second infection with a different strain of *C difficile*. One small study of people with rCDI found that 33% (6/18) of suspected rCDI episodes were due to infection with a different *C difficile* strain, while 67% (12/18) were true recurrences of the same strain of *C difficile* (Tang-Feldman 2003). As these two entities are practically indistinguishable without additional ribotyping, and the difference is clinically irrelevant with regard to treatment, we did not differentiate between these two entities, with the understanding that some 'recurrences' were likely new infections.

We included trials regardless of length of follow-up; we planned that if the last recorded follow-up date was shorter than eight weeks, it will be included in the eight-week outcome data. The eight-week time point is relevant as post-FMT, this is the maximum time frame in which recurrence of symptoms may be considered as a recurrence of CDI (McDonald 2007). Theoretically, if recurrence of diarrheal symptoms and a repeat positive test for *C difficile* occur more than eight weeks after the previous positive test, this is consistent with a new CDI infection after a successful FMT as opposed to an episode of rCDI (McDonald 2007; McDonald 2018).

Types of interventions

We included studies that evaluated FMT for the treatment of rCDI. Fecal microbiota transplantation has been defined as the administration of fecal material containing distal gut microbiota from a healthy donor to a person with a disease or condition related to dysbiosis, or an alteration in their normal gut microbiota (Kelly 2015). We excluded studies that combined FMT with antibiotic treatment during or after the FMT but included studies that used antibiotics prior to FMT. The control group included those who received placebo, the standard of care antibiotic medications, other controls, autologous FMT, or no intervention. Furthermore, we included studies irrespective of the type of stool used (fresh versus thawed, previously frozen stool), volume of stool used, route of administration, number of FMT administrations (single versus multiple infusions), and the number of recurrences of CDI prior to FMT (as long as there was at least one recurrence).

For studies with multiple intervention groups (e.g. factorial design), we included the data such that the only difference between the two groups was donor FMT versus no-donor FMT.

Types of outcome measures

Primary outcomes

1. Proportion of participants with a resolution of rCDI: we considered a participant fulfilling the definition of resolution of rCDI if studies reported either of the two criteria: diarrheal symptoms did not recur after treatment or repeat *C difficile* testing was negative.
2. Serious adverse events, as per the author's definition of a serious adverse event.

Secondary outcomes

A priori planned secondary outcomes:

1. Treatment failure: symptoms of CDI did not resolve after FMT treatment or that reoccurred within two weeks post-FMT.
2. All-cause mortality.

3. Proportion of participants who withdrew from the study.
4. Rate of new CDI infection after a successful FMT, with renewal of diarrheal symptoms and a repeat positive test for *C difficile* more than eight weeks after the previous positive test (McDonald 2007; McDonald 2018).
5. Any adverse event.
6. Quality of life score.
7. Colectomy.

We considered the primary and secondary outcomes at the longest follow-up before the trial was open for analysis. We anticipated that trials would have a follow-up period of at least six weeks. Additional details on definitions of certain primary and secondary outcomes discussed in protocol are available in [Appendix 1](#).

Search methods for identification of studies

Electronic searches

We searched the following databases from their inception using the methods in the *Cochrane Handbook for Systematic Reviews of Interventions* (Lefebvre 2022):

1. Cochrane Central Register of Controlled Trials (CENTRAL, via Ovid; Issue 3, 2022) ([Appendix 2](#));
2. MEDLINE (1946 via Ovid) ([Appendix 3](#));
3. Embase (1974 via Ovid) ([Appendix 4](#));
4. Conference Proceedings Citation Index ([Appendix 5](#));
5. ISRTN Registry (www.isrctn.com/; [Appendix 5](#)).

The literature was conducted on 16 February 2021, and updated on 31 March 2022. We searched the Cochrane Gut Group Specialized Register in February 2021 only and not in March 2022.

Searching other resources

We searched ClinicalTrials.gov (www.clinicaltrials.gov/) for ongoing trials. We also searched the reference sections of previously published randomized trials and meta-analyses on this topic. We contacted authors of published and ongoing studies to seek new or additional data when needed. Of note, ICTRP and ClinicalTrials.gov are both indexed in CENTRAL.

Data collection and analysis

Selection of studies

Two review authors (SHA and AI) independently screened the titles and abstracts of records retrieved from the search to identify potentially eligible studies. The same review authors reviewed the full text of all studies deemed potentially eligible and made a final decision as to inclusion or exclusion. They resolved any discrepancies by discussion and consensus or by consulting a senior review author if disagreement persisted. We used [Covidence](#) software to screen titles and abstracts.

Data extraction and management

Teams of two review authors (from SHA, MM, AI) independently extracted the following data into a pretested Microsoft Excel data extraction form (MS Excel 2018): study authors, date of publication, journal, site of the study, age of participants, definition of the study population (inclusion/exclusion criteria), details of intervention (type, volume, frequency, route of administration

of fecal microbiota transplant, source), outcomes (primary and secondary outcomes), and risk of bias.

We extracted data on an intention-to-treat basis, which considers the initial allocation of participants to an intervention or control group irrespective of whether the participants received the intervention or completed the follow-up (Gupta 2011).

Assessment of risk of bias in included studies

We used the Cochrane RoB 2 tool (current version 22 August 2019) to assess the risk of bias for outcomes of interest in all included studies in the analysis (Higgins 2020; Sterne 2019). The tool considers the following domains:

1. bias arising from the randomization process;
2. bias due to deviations from intended interventions;
3. bias due to missing outcome data;
4. bias in the measurement of the outcome;
5. bias in the selection of the reported result.

The RoB 2 tool also assesses overall risk of bias for an outcome. We used the RoB 2 assessment forms in an Excel tool to assess the risk of bias for each outcome (available at riskofbiasinfo.org). At least two review authors (SHA and MM) answered the signaling questions in the RoB 2 tool for each domain to assess the risk of bias separately for all included studies, for all outcomes reported in the summary of findings table, and the authors compared their assessments. The overall risk of bias was determined based on signaling question responses and any conflicts were discussed with one review author (AI) to reach a final decision. We present the risk of bias summary for each outcome in the results section and provided details regarding the justification for the risk of bias assessment in a supplemental data file. The risk of bias for each outcome was categorized as high risk of bias, some concerns, or low risk of bias. We assessed the risk of bias for outcomes included in the summary of findings table only, namely, resolution of rCDI, serious adverse events, and all-cause mortality. We had planned to assess the risk of bias for the outcome of colectomy; however, none of the included studies reported on this outcome, so this assessment was not completed.

Measures of treatment effect

We calculated the risk ratio (RR) and associated 95% confidence interval (CI) for all dichotomous outcomes. All analyses from RCTs were conducted using an intention-to-treat analysis. We planned to calculate a pooled mean difference (MD) for the continuous outcomes and report them with a 95% CI, but we did not identify any continuous outcomes.

Unit of analysis issues

If we had encountered cross-over trials that were eligible for inclusion, we planned to include data from the first segment of the trial only, before the cross-over occurred. If we had encountered any cluster-randomized trials that were eligible for inclusion, we had planned to synthesize the findings from individually and cluster-randomized trials into a single meta-analysis. We planned to use the cluster adjusted values as reported by the study authors. If the authors did not adjust for the cluster design, we planned to adjust for this by decreasing the effective sample size per guidelines outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2020). However, we did not find

any cross-over trials or cluster-randomized trials that met criteria for inclusion.

For trials with multiple arms, we aimed to include the data in a way that the intervention group received donor-based FMT and the control group received interventions that did not include donor-based FMT. For example, if a study had three study arms and one group received a donor-based FMT, a second group received antibiotic therapy with vancomycin and a third group received antibiotic therapy with fidaxomicin, we included the data in the analysis as donor-based FMT group versus vancomycin group and fidaxomicin group.

Dealing with missing data

Attrition is an important factor that can impact the validity of studies, and differential dropout rates between study groups can lead to biased estimates of effect size (Dumville 2006). We described the missing data, including dropouts and reasons for dropout, as reported by the study authors. We analyzed data from RCTs on an intention-to-treat basis, assuming participants with missing values for the outcomes were treatment failures. For the outcome of resolution of rCDI, this meant that participants lost to follow-up were considered as not having experienced a resolution of rCDI and for the outcomes of serious adverse events and mortality, the participants lost to follow-up were considered as having experienced those outcomes.

We anticipated that study authors may not have reported the standard deviation (SD) for means for continuous outcomes. If SDs had not been available for a mean value, we planned to contact the study authors to request this information. If we were unable to obtain the missing SD from the study authors, we would have calculated the SD from the available data, such as standard error or interquartile range. If no estimates of variance were available for a mean value, we would have used the SD from a similar study with similar sample size, as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2020). However, as our analyses included no continuous outcomes, we did not have to implement these procedures.

Assessment of heterogeneity

We assessed the clinical, methodologic, and statistical heterogeneity amongst studies. We assessed methodologic heterogeneity by comparing components of the risk of bias assessment. We assessed statistical heterogeneity based on forest plots, the I^2 statistic, and the P value for the χ^2 test. We considered heterogeneity to be significant if the P value for χ^2 was less than 0.10 or the I^2 statistic was greater than 60%. We planned to explore potential explanations for heterogeneity using subgroup analyses to explore the distribution of important factors such as maximum number of doses of FMT, route of administration, and the source of FMT, but the number of studies was too small to complete the planned subgroup analyses.

Assessment of reporting biases

We planned to assess potential publication bias based on the symmetry of a funnel plot. We planned to construct funnel plots if the pooled analysis included at least 10 studies. However, there were no analyses with 10 or more studies, so we did not construct any funnel plots.

Data synthesis

We combined data from RCTs for meta-analysis using Review Manager 5 ([Review Manager 2014](#)) and Review Manager Web ([RevMan Web 2020](#)). We pooled the data to obtain a summary estimate in the form of RR for dichotomous outcomes with 95% CIs. We used the random-effects model to pool data but completed a sensitivity analysis employing a fixed-effect model on all primary outcomes to see if this changed the conclusions. We used the intention-to-treat analysis from individual studies. If the intention-to-treat analysis was not reported in the study, we constructed the analysis using the raw values reported in the study. We considered the intention-to-treat analysis as the analysis for an outcome based on initial allocation to the intervention and control group after randomization, irrespective of whether a participant received the intervention or was lost to follow-up. For the outcome of resolution of rCDI, this meant that participants lost to follow-up were considered as not having experienced a resolution of rCDI and for the outcomes of serious adverse events and mortality, the participants lost to follow-up were considered as having experienced those outcomes. We planned to pool continuous data to obtain a pooled MD with 95% CI if all the studies reported the continuous outcome in the same unit. If the studies used different units to report the continuous outcome, we planned to use the standardized mean difference (SMD) with a 95% CI; however, no relevant continuous outcomes were identified. We calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) for all primary and selected secondary outcomes and reported the results for outcomes where the GRADE certainty was at least moderate level.

Subgroup analysis and investigation of heterogeneity

We planned to explore potential explanations for heterogeneity using subgroup analyses. We planned the following a priori subgroup analyses.

1. Clinical setting: outpatient versus hospitalized participants.
2. Storage of stool: fresh stool (of non-stool bank origin) versus frozen then thawed stool (of stool bank origin).
3. Type of donor: related versus unrelated donor.
4. Source of stool: single donor versus pooled donor source of FMT.
5. Route of administration: upper (nasogastric, nasoduodenal, capsule) versus lower (enema, colonoscopy).

All subgroup analyses were at the study and not at the individual level. None of the subgroup analyses were conducted because the number of studies was small (fewer than 10).

Sensitivity analysis

We planned the following a priori sensitivity analyses.

1. Fixed-effect model versus random-effects model.
2. Studies with high risk of bias versus those with low risk of bias/some concerns.

None of the included studies were at high risk of bias so the second of these planned sensitivity analyses was not conducted.

Summary of findings and assessment of the certainty of the evidence

We assessed the overall certainty of the evidence supporting the primary and selected secondary outcomes using the GRADE criteria ([Guyatt 2011](#)). This method of evidence evaluation takes into consideration the impact of the type of studies and each study's risk of bias, indirectness, imprecision, inconsistency, and potential publication biases, providing a rating of the overall certainty of the evidence as high, moderate, low, or very low. We presented the GRADE evaluations as part of [Summary of findings 1](#) for the outcomes of resolution of rCDI, serious adverse events, and all-cause mortality. We had planned to present the GRADE evaluation for the outcome of colectomy, however, none of the included studies reported on this outcome, so this evaluation was not completed for this outcome. We considered the overall risk of bias for each outcome in our grading of the evidence. We provided explanations in the footnotes of the summary of findings table about our decision related to the allocation of certainty of the evidence for a certain outcome.

RESULTS

Description of studies

Results of the search

An initial search was conducted on 16 February 2021 which was updated on 31 March 2022. We identified 1741 records. After removing 476 duplicates, we retained 1265 records for title and abstract screening. After excluding 1194 evidently irrelevant records we assessed 71 full-text records. We excluded 33 studies (41 reports) for reasons outlined in the [Characteristics of excluded studies](#) table. Three studies are awaiting classification and 13 studies are ongoing studies. We included six studies (14 reports) in the review ([Cammaraota 2015](#); [Hota 2017](#); [Hvas 2019](#); [Kelly 2016](#); [Rode 2021](#); [van Nood 2013](#)). This is summarized in the PRISMA flow diagram ([Figure 1](#)).

Figure 1. PRISMA flow diagram.




Figure 1. (Continued)

6 studies included
in quantitative
synthesis
(meta-analysis)

Included studies

Six RCTs assessed FMT for the treatment of rCDI (Cammarota 2015; Hota 2017; Hvas 2019; Kelly 2016; Rode 2021; van Nood 2013). See Characteristics of included studies table for full details.

Study type

All the studies were individual RCTs. Five studies were open-label and one study was a double-blinded (Kelly 2016). Four studies were single-center (Cammarota 2015; Hota 2017; Hvas 2019; van Nood 2013), and two were multicenter studies (Kelly 2016; Rode 2021). Three studies had two intervention groups (Cammarota 2015; Hota 2017; Kelly 2016), and three had more than two intervention groups (Hvas 2019; Rode 2021; van Nood 2013).

We combined all the comparisons groups without donor-based FMT as one group for a meta-analysis of donor-based FMT versus control and the details of this analysis are available in the notes section of each study in the Characteristics of included studies table.

Country

The included studies were conducted in five different countries, with two studies conducted in Denmark (Hvas 2019; Rode 2021), and one each in Canada (Hota 2017), the Netherlands (van Nood 2013), Italy (Cammarota 2015), and the US (Kelly 2016).

Study population

Five studies excluded people who were severely immunocompromised; one study did not explicitly describe it as an exclusion criterion (Hvas 2019). Three studies excluded people who were admitted to intensive care units (Cammarota 2015; Hota 2017; van Nood 2013). Two studies excluded people with severe fulminant colitis (Hota 2017; Hvas 2019). All the studies excluded pregnant women.

Age and gender

All studies were conducted on adults. The percentage of men in the studies ranged from 20% (Kelly 2016) to 57% (van Nood 2013). The mean age of participants ranged from 52 years (Kelly 2016) to 73 years (Cammarota 2015; Hota 2017; Rode 2021).

History of prior medication treatment

All six studies included people who had previously received some form of antibiotic treatment for CDI or rCDI (or both). Two studies included people who had previously been treated with vancomycin (Hota 2017; Kelly 2016). Three studies included people who had previously been treated with vancomycin or metronidazole (or both) (Cammarota 2015; van Nood 2013; Rode 2021). One study included people who had previously been treated with vancomycin

or metronidazole or fidaxomicin (or a combination of these) (Hvas 2019).

Use of immunosuppressive medications

Five studies excluded people who were immunocompromised (Cammarota 2015; Hota 2017; Kelly 2016; Rode 2021; van Nood 2013), with only Hvas 2019 including 10 participants who were receiving immunosuppressive therapy out of the total of 64 enrolled, which were similarly distributed between the FMT group (4/24 or 17%) and comparison group (6/40 or 15%).

Intervention

Indications for fecal microbiota transplantation

All six studies used FMT for the treatment of rCDI. Four studies required a person to have had at least one recurrence of CDI (Cammarota 2015; Hvas 2019; van Nood 2013; Rode 2021), while one study enrolled only people who had two or more recurrences (Hota 2017), and one study only enrolled people who had three or more recurrences (Kelly 2016). The overall reported number of rCDI episodes prior to inclusion in the respective trials differed between studies, with a range of the mean from approximately three (Cammarota 2015) in one study to as high as six episodes in another study (Rode 2021).

Donors

All six studies used feces produced by apparently healthy donors. In three studies, the donors were not related to the study participants (Hvas 2019; Rode 2021; van Nood 2013), and in three studies some of the donors were related to the recipients and some were not (Cammarota 2015; Hota 2017; Kelly 2016). All studies used one donor for each FMT and did not use pooled stool from multiple donors to perform one FMT.

Route of administration

The route of administration was to the upper gastrointestinal tract via a nasoduodenal tube in one study (van Nood 2013). One study used either nasojejunal or colonoscopic delivery depending on a clinical determination of whether the patient could tolerate a colonoscopy (Hvas 2019). Two studies used administration by enema (Hota 2017; Rode 2021), and two used only colonoscopic delivery (Cammarota 2015; Kelly 2016).

Number of administrations of fecal microbiota transplantation

Three studies limited the FMT recipients to a single administration of FMT within the primary analysis (Hota 2017; Hvas 2019; Kelly 2016), whereas the other three studies allowed multiple FMT administrations (Cammarota 2015; Rode 2021; van Nood 2013). Within van Nood 2013, participants with pseudomembranous colitis were potentially allowed to receive an unlimited number

of administrations, as the revised protocol allowed for repeat administrations until visible pseudomembranes on colonoscopy were resolved.

Weight of stool

The weight of stool used in each FMT administration ranged from 50 g (Hota 2017; Hvas 2019; Rode 2021) to a mean of 152 g (Cammarota 2015).

Volume of stool

The volume of FMT delivered in an administration ranged from 170 mL (Rode 2021) to 500 mL (Cammarota 2015; Hota 2017; Kelly 2016; van Nood 2013). Hvas 2019 did not explicitly state the volume of FMT delivered.

Colonic lavage

A colonic lavage was part of the protocol in five studies (Cammarota 2015; Hvas 2019; Kelly 2016; Rode 2021; van Nood 2013). Hota 2017 did not perform colonic lavage.

Follow-up

The follow-up time for measurement of the primary outcome ranged from eight weeks (Hvas 2019; Kelly 2016) to 17 weeks (Hota 2017).

Comparison

Three studies had two non-FMT comparator arms, one of which was a vancomycin regimen (Hvas 2019; Rode 2021; van Nood 2013). The other comparator arm included vancomycin combined with bowel lavage in van Nood 2013, treatment with a 10-day regimen of fidaxomicin in Hvas 2019, and a combination of vancomycin followed by a daily enema for three consecutive days containing a mixture of 12 well-characterized gut bacterial strains sensitive to either metronidazole or ampicillin (a treatment termed bacteriotherapy) in Rode 2021.

Five studies had a comparison group that received vancomycin (Cammarota 2015; Hota 2017; Hvas 2019; Rode 2021; van Nood 2013). Two studies used a tapering dose after 14 days of standard therapy (Cammarota 2015; Hota 2017), while the other used the standard dose without a taper (Hvas 2019; Rode 2021; van Nood 2013).

Excluded studies

Twenty-one excluded studies used an ineligible comparator such as high-dose versus low-dose FMT, comparing various FMT delivery systems, and comparing different types of FMT (fresh, frozen, lyophilized, lactobacillus-enriched). Six studies did not fulfill the criteria based on the study design. One study provided the intervention for an ineligible indication. See the [Characteristics of excluded studies](#) table for details.

Studies awaiting classification

Four studies are awaiting classification (Dubberke 2018; Kao 2019; NCT03353506; NCT03548051).

One study was terminated and details of the results were not available even after contact with investigators (NCT03548051). Kao 2019 was a small pilot study that met the inclusion criteria but there was insufficient information for us to complete the risk of bias assessment and include the data in the analysis. NCT03353506 was

a small pilot study that has been completed but there appeared to be no published data at the time of this publication.

Dubberke 2018 may qualify for inclusion in subsequent versions of this systematic review and meta-analysis. Based on the proprietary nature and our lack of access to the exact methods of collection of donor stool, processing, and shipping of the RBX2660 microbiota suspension, it is unclear at the time of the publication of this text whether RBX2660 microbiota suspension technically qualifies as FMT. We will contact study authors for further clarification in this regard.

Ongoing studies

Thirteen studies are ongoing (Drekonja 2021; EUCTR2015-003062-82-DK; NCT02255305; NCT02774382; NCT03005379; NCT03053505; NCT03806803; NCT03970200; NCT04885946; NCT04960306; NCT05077085; NCT05201079; NCT05266807).

Risk of bias in included studies

We included the risk of bias assessment in the forest plots for each of the outcomes included in [Summary of findings 1](#) and discussed the risk of bias in the [Effects of interventions](#) section for each of these outcomes. We also included a supplemental data (Microsoft Excel) file with details of the risk of bias assessment data. A brief summary of the risk of bias assessment across the outcomes is described below.

The results of risk of bias assessments were similar across outcomes in the included studies. Even though we had concerns about the lack of description of randomization methods for two studies (Hota 2017; Hvas 2019), these studies were preregistered and they had randomized groups that looked similar at baseline, so we did not assign a higher risk of bias for them for any of the outcomes considered in the risk of bias assessment. Five studies were open-label (Cammarota 2015; Hota 2017; Hvas 2019; Rode 2021; van Nood 2013). We decided that lack of blinding in these studies did not increase the risk of bias because the outcomes of rCDI resolution, serious adverse events, and mortality were fairly objective hence the assessment of these outcomes was unlikely to be influenced by knowledge of intervention received. Two studies performed a per-protocol analysis rather than an intention-to-treat analysis (Hota 2017; van Nood 2013). All other studies performed an intention-to-treat analysis in addition to per-protocol or modified intention-to-treat analysis. We recreated the intention-to-treat analysis where studies reported a per-protocol analysis. We did not assign a high risk of bias due to deviations from allocated groups. For the outcome of resolution of rCDI, this meant that participants lost to follow-up were considered as not having experienced a resolution of rCDI and for the outcomes of serious adverse events and mortality, the participants lost to follow-up were considered as having experienced those outcomes. We performed sensitivity analyses comparing the intention-to-treat results with the as-available values for all outcomes in the summary of findings table ([Analysis 1.3](#); [Analysis 1.7](#); [Analysis 1.11](#)). All included studies were registered on a trial registry and we had low concern for selective reporting of outcomes.

Effects of interventions

See: [Summary of findings 1 Summary of findings table - Fecal microbiota transplantation \(FMT\) compared to control in adults with recurrent Clostridioides difficile infection \(rCDI\)](#)


Primary outcomes

Proportion of participants with resolution of recurrent C difficile infections

All six included studies reported data on the proportion of participants with the resolution of rCDI. The data included 320

participants, 133 in the FMT group and 187 in the control group. Pooled results showed that treatment with FMT likely leads to a large increase in the proportion of participants with a resolution of rCDI with FMT compared to control (RR 1.92, 95 % CI 1.36 to 2.71; P = 0.02, I² = 63%; NNTB 3; moderate-certainty evidence; [Analysis 1.1](#); [Figure 2](#); [Summary of findings 1](#)). We downgraded the certainty of evidence due to imprecision.

Figure 2. Forest plot of comparison: 1 Fecal microbiota transplantation (FMT) vs control for the treatment of recurrent Clostridioides difficile infections (rCDI), outcome: 1.1 Resolution of rCDI.



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

Sensitivity and subgroup analyses

A fixed-effect model had a similar result to the primary random-effects model used in this review (RR 1.92, 95 % CI 1.58 to 2.34; P = 0.02, I² = 63%; 6 studies, 320 participants; [Analysis 1.2](#)).

A post-hoc sensitivity analysis using as-available data found similar results to the intention-to-treat analysis used in this review (RR 1.89, 95 % CI 1.31 to 2.73; P = 0.008, I² = 68%; 6 studies, 313 participants; [Analysis 1.3](#)).

We performed a sensitivity analysis excluding immunocompromised participants. Of note, [Hvas 2019](#) was the only study that enrolled immunocompromised participants, and this study did not present the data in a way that allowed us to distinguish results between immunocompromised and immunocompetent participants. Excluding this study, the analysis found similar results to the analysis that included immunocompromised participants for resolution of rCDI (RR 1.81,

95 % CI 1.23 to 2.66; P = 0.02, I² = 65%; 5 studies, 256 participants; [Analysis 1.4](#)).


We had planned to conduct a sensitivity analysis comparing studies with a high risk of bias versus those with low risk of bias/some concerns; however, there were no studies with high risk of bias.

We did not conduct any of the planned subgroup analyses as there were too few studies.

Serious adverse events

All six included studies reported data on serious adverse event rate. The data included 320 participants, 133 in the FMT group and 187 in the control group. The pooled results showed that FMT probably results in a slight reduction in serious adverse events; however, the CIs around the summary estimate were wide so we downgraded the certainty of evidence one level due to imprecision (RR 0.73, 95% CI 0.38 to 1.41; P = 0.24, I² = 26%; NNTB 12; moderate-certainty evidence; [Analysis 1.5](#); [Figure 3](#); [Summary of findings 1](#)).

Figure 3. Forest plot of comparison: 1 Fecal microbiota transplantation (FMT) vs control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), outcome: 1.2 Serious adverse events.



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

Sensitivity and subgroup analyses

A fixed-effect model had a similar result to the primary random-effects model used in this review (RR 0.64, 95 % CI 0.38 to 1.09; P = 0.24, I² = 26%; 6 studies, 320 participants; [Analysis 1.6](#)).

A post-hoc sensitivity analysis using as-available data found similar results to the intention-to-treat analysis used in this review (RR 0.72, 95 % CI 0.37 to 1.38; P = 0.32, I² = 14%; 6 studies, 314 participants; [Analysis 1.7](#)).

We performed a post-hoc sensitivity analysis excluding immunocompromised participants. Of note, [Hvas 2019](#) was the only study that enrolled immunocompromised participants, and this study did not present the data in a way that allowed us to distinguish results between immunocompromised and immunocompetent participants. Excluding this study, the analysis showed similar results to the analysis that included immunocompromised participants for SAE (RR 0.72, 95 % CI 0.30 to 1.74; P = 0.16, I² = 39%; 5 studies, 256 participants; [Analysis 1.8](#)).

We had planned to conduct a sensitivity analysis comparing studies with a high risk of bias versus those with low risk of bias/some concerns; however, there were no studies with high risk of bias.

We did not conduct any of the planned subgroup analyses as there were too few studies.

Secondary outcomes

Treatment failure

None of the included studies explicitly reported treatment failure.

All-cause mortality

All six studies reported data on all-cause mortality. The data included 320 participants, 133 in the FMT group, and 187 in the control group. Pooled data showed that FMT may lower all-cause

mortality; however, the CIs around the summary estimates were wide so we downgraded the certainty of the evidence because of very serious imprecision. None of the included studies were at high risk of bias for this outcome (RR 0.57, 95% CI 0.22 to 1.45; P = 0.48, I² = 0%; NNTB 20; low-certainty evidence; [Analysis 1.9](#); [Summary of findings 1](#)).

Sensitivity and subgroup analysis

A fixed-effect model showed a similar result to the primary random-effects model used in this review (RR 0.52, 95 % CI 0.22 to 1.23; P = 0.48, I² = 0%; 6 studies, 320 participants; [Analysis 1.10](#)).

A post-hoc sensitivity analysis using as-available data found similar results to the intention-to-treat analysis used in this review (RR 0.50, 95 % CI 0.17 to 1.46; P = 0.68, I² = 0%; 6 studies, 314 participants; [Analysis 1.11](#)).

We performed a post-hoc sensitivity analysis excluding immunocompromised participants. Of note, [Hvas 2019](#) was the only study that enrolled immunocompromised participants, and this study did not present the data in a way that allowed us to distinguish results between immunocompromised and immunocompetent participants. Excluding this study, the analysis showed similar results to the analysis that included immunocompromised participants for all-cause mortality (RR 0.57, 95 % CI 0.22 to 1.45; P = 0.48, I² = 0%; 5 studies, 256 participants; [Analysis 1.12](#)).

We had planned to conduct a sensitivity analysis comparing studies with a high risk of bias versus those with low risk of bias/some concerns; however, there were no studies with high risk of bias.

We did not conduct any of the planned subgroup analyses as there were too few studies.

Proportion of participants who withdrew from the study

Six studies reported data on the number of participants who withdrew from the study. The data included 320 participants, 133 in the FMT group and 187 in the control group. The rates of withdrawal from the study were similar in both the groups (RR 0.75, 95% CI 0.17 to 3.28; $P = 0.52$, $I^2 = 0\%$; 6 studies, 320 participants; [Analysis 1.13](#)).

Rate of new *Clostridioides difficile* infection

None of the studies reported the rate of new CDI infections.

Any adverse event

All six studies reported data on any adverse events. A total of 111 participants in the FMT group experienced 189 adverse events, whereas 163 participants in the control group experienced 164 adverse outcomes. Because one participant could experience multiple simultaneous mild adverse events that were not mutually exclusive, the planned statistical analyses would not have been valid. Therefore, [Table 1](#) shows a breakdown of adverse events extracted from the text of the primary studies. The most commonly described mild adverse events in the FMT group were abdominal pain, bloating, and diarrhea.

Quality of life score

None of the studies reported quality of life scores.

Colectomy

None of the studies reported data on colectomy rates.

Post-hoc secondary outcomes

Microbiome outcomes

Three studies reported analysis of microbiome outcomes in FMT recipients. [Table 2](#) gives the summary of methods used to assess the microbiome-related outcomes as well as a summary of the key findings from the included studies.

DISCUSSION

Summary of main results

This review synthesized findings from six RCTs, consisting of 320 participants, which assessed the benefits and harms of FMT in the treatment of immunocompetent adults with rCDI. There is moderate-certainty evidence that in immunocompetent adults with rCDI, the use of FMT likely leads to a large increase in resolution of rCDI in FMT-receiving participants compared to controls. Fecal microbiota transplantation likely decreases the rates of serious adverse and may reduce all-cause mortality; however, the summary estimates for these outcomes were imprecise. Elimination of the study that included some immunocompromised participants did not alter these conclusions, but, based on the low number of immunocompromised participants enrolled in the included studies, conclusions could not be drawn about the benefits or harms of FMT for rCDI in the immunocompromised population at this time. Data were not available for all the prespecified outcomes. The number of included studies was small and, therefore, we did not complete any of the planned subgroup analyses.

Overall completeness and applicability of evidence

The use of FMT for the treatment of rCDI seems biologically plausible. Data from observational studies have shown that the risk of CDI is increased in people with dysbiosis, such as after the use of antibiotics, proton pump inhibitors, immunosuppression, and hospitalization ([Crobach 2018](#); [Fekety 1997](#)). The use of FMT seems to reverse the dysbiosis as shown in some of the included studies in this review where the microbiome of the responders seemed to mirror the donors, as summarized in [Table 2](#) ([Hota 2017](#); [Kelly 2016](#); [van Nood 2013](#)).

Many observational studies have been published on this topic, and support FMT as efficacious for the treatment of rCDI; however, these studies did not meet criteria for inclusion in this review. All included studies in this review were preregistered on a trial registry and five were stopped early due to futility. All studies contributed data to the primary outcome and five studies showed convincing evidence in favor of the intervention that was depicted in the summary estimate of the meta-analysis for the outcome of the resolution of rCDI. The data on serious adverse events and all-cause mortality from the included studies showed that FMT may be safe in the short term for the treatment of rCDI. However, it is important to note that the number of events was small and the CIs of the summary estimate included both a decreased and a possible increased risk for these outcomes. Randomized controlled trials may not be the ideal study design to assess the risk of serious adverse events and long-term outcomes, and database registries with a larger sample size and longer follow-up may be more useful for this purpose. One recent report from the FMT national registry in the US reported effectiveness and safety data for 259 participants at one- and six-month follow-ups, confirming effectiveness and showing a favorable safety profile of FMT for treatment of rCDI ([Kelly 2021](#)). The most commonly reported adverse events in the [Kelly 2021](#) study were abdominal pain, diarrhea, and bloating, similar to those reported in the included studies in this review. Moreover, the US FDA recently issued a safety alert about the use of FMT due to reports of cases of transmission of multiple-drug-resistant organisms and mortality in people who received FMT ([FDA 2019](#); [FDA 2020a](#)).

The longest follow-up in any of the included studies was 17 weeks, so this review does not provide evidence regarding the long-term safety of FMT. Evidence regarding the long-term safety of FMT was reported in one recent observational cohort study that included data from 609 people who received FMT ([Saha 2021](#)). This study reported safety data at one and two years after FMT. Diarrhea and constipation were commonly reported symptoms in this cohort after FMT. The study also reported that 73 people who received an FMT developed a new diagnosis over the period of follow-up; however, these diagnoses were all deemed as unrelated to FMT and this paper did not include a comparator group so no solid conclusion about the risk of developing new diagnoses as a result of FMT could be drawn from this study ([Saha 2021](#)).

We had planned five a priori subgroup analyses, but none of these could be conducted due to the low number of studies that met the inclusion criteria. Therefore, we cannot comment if the efficacy and safety of FMT will differ based on clinical setting (outpatient versus hospitalized people); storage of stool (fresh stool of non-stool bank origin versus frozen then thawed stool of stool bank origin); type of donor (related versus unrelated); source of stool (single donor versus pooled donor source of FMT); route of FMT delivery (to the

upper gastrointestinal tract including nasogastric, nasoduodenal, and capsule routes versus delivery to the lower gastrointestinal tract via enema and colonoscopy).

While our protocol allowed for the inclusion of both children and adults with rCDI (Imdad 2021), all six studies that met the criteria for inclusion excluded children from enrolling. Therefore, the results of this review are applicable to the adult population only. Five studies excluded people who were severely immunocompromised. Therefore, the results supported by this review should be used with caution for people who are severely immunocompromised. Similarly, all the studies excluded pregnant women, and the use of FMT during pregnancy should be used with extreme caution.

Quality of the evidence

The GRADE criteria consider the type of studies, risk of bias, indirectness, inconsistency (i.e. unexplained heterogeneity), imprecision, and potential publication bias (Guyatt 2011). Using the GRADE criteria, the overall certainty of the evidence was moderate for resolution of rCDI and serious adverse events, and low for all-cause mortality.

Five studies were open-label (Cammarota 2015; Hota 2017; Hvas 2019; Rode 2021; van Nood 2013). We did not assign these studies a high risk of bias because the outcomes of rCDI resolution, serious adverse events, and mortality were considered objective.

Some included studies performed a per-protocol analysis rather than an intention-to-treat analysis. We recreated the intention-to-treat analysis where applicable and did not assign a high risk of bias due to deviations from allocated groups. We created the intention-to-treat analysis for studies where data for follow-up were missing. For the outcome of resolution of rCDI, this meant that participants lost to follow-up were considered as not having experienced a resolution of rCDI and for the outcomes of serious adverse events and mortality, the participants lost to follow-up were considered as having experienced those outcomes. We performed a sensitivity to assess our assumption and the summary estimate were similar between recreated intention-to-treat analyses and as-available analyses.

Five studies were stopped early due to futility (Cammarota 2015; Hota 2017; Kelly 2016; Rode 2021; van Nood 2013). Four of these studies determined that further recruitment of participants would not change the results and that FMT is an effective intervention compared to control (Cammarota 2015; Kelly 2016; Rode 2021; van Nood 2013). One study was stopped due to lack of effect (Hota 2017). We did not consider early termination of trials as the high risk of bias because of the apparent reproducibility of similar results across trials including the one that was completed (Hvas 2019).

In summary, even though we noted some issues in risk of bias assessment as noted above, we did not downgrade the certainty of the evidence for risk of bias for any of the outcomes. All six studies were well conducted, and the measured outcomes were fairly objective. Consequently, it is less likely that the observed effect of FMT for treatment of rCDI is because of bias in the included studies.

The outcome of resolution of rCDI had a statistical heterogeneity of 63% based on the I^2 value. We did not downgrade the certainty of evidence due to inconsistency for this outcome because this

statistical heterogeneity was likely due to differences in the magnitude of effect as the direction of effect was in favor of the intervention in five of the studies, and it was clinically meaningful. However, we downgraded the certainty of evidence due to imprecision as the CIs around the summary estimate were wide.

We downgraded the certainty of the evidence for serious adverse events and all-cause mortality for imprecision because the number of events was small, and the confidence of the summary estimate included both a reduced and potentially increased risk of the outcome.

Potential biases in the review process

This review used standard methodologic procedures expected by Cochrane (Higgins 2020). We searched for both published studies and ongoing studies. As the number of included studies was fewer than 10, we could not perform analyses to assess for potential publication bias.

Three studies had more than one non-FMT comparator group. We combined these subgroups to obtain a donor-based FMT versus non-donor-based FMT comparison. We specified this approach in our protocol (Imdad 2021), and described these decisions for each study in the [Characteristics of included studies](#) table. To investigate this approach further, we planned to conduct a post hoc subgroup analysis based on comparator but as there were fewer than 10 studies, this subgroup analysis was not conducted. An alternative approach to assess the efficacy of FMT versus other treatments would be to perform a network meta-analysis and one recent network-analysis indicated that FMT might be the best therapy among all the available therapies to treat rCDI (Dembrowszky 2020).

The FMT group in our analysis combined studies that only allowed a single FMT infusion with studies that allowed for the potential of multiple FMT infusions. One recent RCT showed that multiple FMT infusions might help cure the relapsing colitis related to rCDI (Ianiro 2018). Therefore, we may have overestimated the efficacy of a single FMT infusion by grouping it with studies that allowed for multiple FMT infusions if the participants' rCDI symptoms did not resolve with the first infusion. We had planned to perform a post-hoc subgroup analysis based on the number of FMTs allowed but were unable to conduct this as the number of included studies was fewer than 10 and it was very unlikely that an investigation of heterogeneity would produce useful findings unless there are at least 10 studies in a meta-analysis.

Agreements and disagreements with other studies or reviews

Multiple systematic reviews have been published on the efficacy and safety of FMT for the treatment of rCDI (Baunwall 2020; Pomares Bascuñana 2021) including network meta-analyses (Dembrowszky 2020; Rokkas 2019). The reviews by Baunwall 2020 and Pomares Bascuñana 2021 considered both randomized and non-randomized studies but came to a similar conclusion as the network meta-analyses (Dembrowszky 2020; Rokkas 2019), which also agree with the findings of our systematic review and meta-analysis that FMT is likely to be highly efficacious for the treatment of rCDI.

The objectives of our review were mainly related to the efficacy and safety of FMT for the treatment of rCDI. Even though we

planned several subgroup analyses to differentiate characteristics of FMT in terms of the optimal route of administration, frequency, type of donor, and other variables, unfortunately, there were not enough studies in these subgroup analyses to make any conclusive statements. Other reviews and studies have addressed some of these questions. For example, [Ramai 2021](#) assessed the different routes of administration of FMT for the treatment of rCDI and included 26 studies with 1309 participants. Fecal microbiota transplantation was found to be highly efficacious irrespective of the route of administration; however, the administration via colonoscopy seems to have the highest cure rate of about 94.8% (95% CI 92.4% to 96.8%) while the nasogastric tube had lower cure rate of 78.1% (95% CI 71.6% to 84.1%). The number of studies in [Ramai 2021](#) was small in each of the subgroups other than colonoscopy subgroup, so the observed difference in the nasogastric tube may be explained by a paucity of studies. The raw data in our analysis showed approximately a 77% cure rate of rCDI treated with FMT. This appears to be roughly similar but slightly lower than the cure rate found in other systematic reviews and network meta-analyses, where resolution of rCDI rates ranged between 82% and 91% ([Bauwall 2020](#); [Dembrowszky 2020](#); [Pomares Bascuñana 2021](#); [Ramai 2021](#)).

AUTHORS' CONCLUSIONS

Implications for practice

In immunocompetent adults with recurrent *Clostridioides difficile* infection (rCDI), fecal microbiota transplantation (FMT) probably leads to a large increase in the resolution of rCDI compared to alternative treatments such as antibiotics. Fecal microbiota transplantation probably leads to a small decrease in the rates of serious adverse events and may decrease all-cause mortality in people with rCDI; however, the number of events was small and an increased risk of these outcomes cannot be ruled out. Additional data from large national registry databases may be required to assess the potential short-term and long-term risks with using FMT for treatment of rCDI in clinical practice. Based on the low number of immunocompromised participants enrolled in the included studies, conclusions cannot be drawn about the benefits or harms of FMT for rCDI in the immunocompromised population at this time.

Implications for research

Five of the included studies excluded people who were immunocompromised and additional data from clinical trials might be required in people with rCDI who have HIV, solid organ transplant, stem cell transplant, those undergoing chemotherapy ([Abu-Sbeih 2019](#)), and those on long-term immunosuppressive medications. Similarly, there is paucity of data on safety of FMT use in people with fulminant colitis requiring admission to the intensive care unit as most of the included studies excluded such individuals.

None of the included studies enrolled children; however, given the efficacy of FMT for rCDI reported in this and other studies, it would be morally dubious to recommend studies with a comparator arm with no treatment in this population. The safety data reported in the included studies were based on short-term follow-up, and the same safety profile was confirmed in a recent publication from data from a national registry ([Kelly 2021](#)); however, future studies with a comparator arm are needed to establish the long-term safety of FMT ([Saha 2021](#)). Finally, new therapies based on particular strains of bacteria that may reverse the dysbiosis require further investigations as such therapies can simplify the bacteriotherapy for rCDI by eliminating the need for donors and minimizing the risk of exposure to potentially harmful micro-organisms ([Rode 2021](#)).

ACKNOWLEDGEMENTS

Cochrane Gut supported the review authors in the development of this review.

The following people conducted the editorial process for this article:

- Sign-off Editor (final editorial decision): Paul Moayyedi; McMaster University, Canada; Co-ordinating Editor of the Cochrane Gut Group;
- Managing Editor (selected peer reviewers, provided comments, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Lara Kahale and Sam Hinsley, Cochrane Central Editorial Service;
- Editorial Assistant (conducted editorial policy checks and supported editorial team): Lisa Wydrzynski, Cochrane Central Editorial Service;
- Copy Editor (copy-editing and production): Anne Lawson, Central Production Service, Cochrane;
- Peer-reviewers (provided comments and recommended an editorial decision): Christian Lodberg Hvas, Aarhus University Hospital, Denmark (clinical/content review); Muhammad Abdel-Gawad, Al-Azhar University, Assiut, Egypt (clinical/content review); Rapat Pittayanon, Chulalongkorn University, Bangkok, Thailand (clinical/content review); George Lillington (consumer review), Rachel Richardson, Associate Editor, Cochrane Evidence Production and Methods directorate (methods review);
- One additional peer reviewer provided search peer review, but chose not to be publicly acknowledged.

The search strategies were designed and run by Yuhong Yuan (Information Specialist, Cochrane Gut) on 16 February 2021.

The literature search was updated on 31 March 2022 by Abigail Smith (SUNY Upstate Medical University, Health Sciences Library, Syracuse, New York, USA).

REFERENCES

References to studies included in this review

Cammarota 2015 {published data only}

Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Alimentary Pharmacology and Therapeutics* 2015;**41**(9):835-43. [DOI: [10.1111/apt.13144](https://doi.org/10.1111/apt.13144)]

Hota 2017 {published data only}

Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent *Clostridium difficile* infection: an open-label, randomized controlled trial. *Clinical Infectious Diseases* 2017;**64**(3):265-71. [DOI: [10.1093/cid/ciw731](https://doi.org/10.1093/cid/ciw731)]

Hvas 2019 {published data only}

* Hvas CL, Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent *Clostridium difficile* infection. *Gastroenterology* 2019;**156**(5):1324-32. [DOI: [10.1053/j.gastro.2018.12.019](https://doi.org/10.1053/j.gastro.2018.12.019)]

Kelly 2016 {published data only}

* Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent *Clostridium difficile* infection – a randomized trial. *Annals of Internal Medicine* 2016;**165**(9):609-16. [DOI: [10.7326/M16-0271](https://doi.org/10.7326/M16-0271)]

Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete microbiota engraftment is not essential for recovery from recurrent *Clostridium difficile* infection following fecal microbiota transplantation. *mBio* 2016;**7**(6):e01965-16. [PMID: 27999162]

Rode 2021 {published data only}

* Rode AA, Chehri M, Krogsgaard LR, Heno KK, Svendsen AT, Ribberholt I, et al. Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent *Clostridioides difficile* infections. *Alimentary Pharmacology and Therapeutics* 2021;**53**(9):999-1009. [DOI: [10.1111/apt.16309](https://doi.org/10.1111/apt.16309)]

van Nood 2013 {published data only}

van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *New England Journal of Medicine* 2013;**368**(5):407-15. [DOI: [10.1056/NEJMoa1205037](https://doi.org/10.1056/NEJMoa1205037)]

References to studies excluded from this review

Allegretti 2016 {published data only}

* Allegretti JR, Fischer M, Papa E, Elliott R J, Klank J, Mendolia G, et al. Fecal microbiota transplantation delivered via oral capsules achieves microbial engraftment similar to traditional delivery modalities: safety, efficacy and engraftment

results from a multi-center cluster randomized dose-finding study. *American Gastroenterological Association Abstracts* 2016;**150**(4):S540. [DOI: [10.1016/S0016-5085\(16\)31855-8](https://doi.org/10.1016/S0016-5085(16)31855-8)]

Allegretti JR, Fischer M, Papa E, Elliott R J, Klank J, Mendolia G, et al. Fecal microbiota transplantation delivered via oral capsules achieves microbial engraftment similar to traditional delivery modalities: safety, efficacy and engraftment results from a multi-center cluster randomized dose-finding study. *Digestive Disease Week* 2016;**1**:S540.

Allegretti 2019 {published data only}

* Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, et al. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent *Clostridium difficile* infection: a comparative cohort analysis of high and low dose. *Digestive Diseases and Sciences* 2019;**64**:1672-8. [DOI: [10.1007/s10620-018-5396-6](https://doi.org/10.1007/s10620-018-5396-6)]

Cicerone 2017 {published data only}

Cicerone C, Bruno G, Lamonaca L, D'Abramo A, Oliva A, Zingaropoli MA. Fecal microbiota transplantation via enema for recurrent *Clostridium difficile* infection modulates the inflammatory host response and restores intestinal dysbiosis. *Digestive and Liver Disease* 2017;**49**:e103. [DOI: [10.1016/S1590-8658\(17\)30354-7](https://doi.org/10.1016/S1590-8658(17)30354-7)]

Dupont 2017 {published data only}

Dupont H, Jiang ZD, Alexander A, Ajami N, Petrosino JF, DuPont AW, et al. Lyophilized fecal microbiota transplantation capsules for recurrent *Clostridium difficile* infection. *Open Forum Infectious Diseases* 2017;**4**(Suppl 1):S381. [DOI: [10.1093/ofid/ofx163.943](https://doi.org/10.1093/ofid/ofx163.943)]

Fischer 2015 {published data only}

Fischer M, Allegretti JR, Smith M, Klank MJ, Mendolia G, Vo E, et al. A multi-center, cluster randomized dose-finding study of fecal microbiota transplantation capsules for recurrent *Clostridium difficile* infection. *United European Gastroenterology Journal* 2015;**3**(6):565-66. [DOI: [10.1177/2050640615616068](https://doi.org/10.1177/2050640615616068)]

Friedman-Korn 2018 {published data only}

Friedman-Korn T, Livovsky DM, Maharshak N, Aviv CN, Paz K, Bar-Gil SA, et al. Fecal transplantation for treatment of *Clostridium difficile* infection in elderly and debilitated patients. *Digestive Diseases and Sciences* 2018;**63**:198-203. [DOI: [10.1007/s10620-017-4833-2](https://doi.org/10.1007/s10620-017-4833-2)]

Garza-Gonzalez 2019 {published data only}

* Garza-Gonzalez E, Mendoza-Olazarán S, Morfin-Otero R, Ramirez-Fontes A, Rodriguez-Zulueta P, Flores-Trevino S, et al. Intestinal microbiome changes in fecal microbiota transplant (FMT) vs. FMT enriched with *Lactobacillus* in the treatment of recurrent *Clostridioides difficile* infection. *Canadian Journal of Gastroenterology and Hepatology* 2019;**2019**:4549298. [ARTICLE ID: 4549298] [DOI: [10.1155/2019/4549298](https://doi.org/10.1155/2019/4549298)]

Ianiro 2018 {published data only}

Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory *Clostridium difficile* infection – single versus multiple infusions. *Alimentary Pharmacology and Therapeutics* 2018;**48**:152-9.

* Ianiro G, Masucci L, Quaranta G, Simonelli C, Rizzatti G, Lopetuso L, et al. Randomized clinical trial: single-infusion FMT versus multiple-infusion FMT for the treatment of severe *C. difficile* infection. *Digestive and Liver Disease* 2018;**50**(2 Suppl):e66-7.

Jiang 2017 {published data only}

Jiang ZD, Ajami NJ, Petrosino JF, Jun G, Hanis CL, Shah M, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent *Clostridium difficile* infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. *Alimentary Pharmacology and Therapeutics* 2017;**45**:899-908. [DOI: [10.1111/apt.13969](https://doi.org/10.1111/apt.13969)]

Jiang 2018b {published data only}

* Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Shi KS, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent *Clostridium difficile* infection: a randomized clinical trial. *PLOS One* 2018;**13**(11):e0205064. [DOI: [10.1371/journal.pone.0205064](https://doi.org/10.1371/journal.pone.0205064)]

Jiang 2018c {published data only}

Jiang ZD, Jenq R, Ajami N, DuPont HL. The effect of type of inoculum and administration route of fecal microbiota transplantation in subjects with recurrent *Clostridium difficile* infection. *Gastroenterology* 2018;**154**(6):S892.

JPRN-UMIN000016900 {published data only}

* JPRN-UMIN000016900. Fecal microbiota transplantation for *Clostridium difficile* infection. trialssearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000016900 (first received 24 March 2015).

JPRN-UMIN000019181 {published data only}

* JPRN-UMIN000019181. Fecal microbiota transplantation for refractory *Clostridium difficile* infection. trialssearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000019181 (first received 1 November 2015).

JPRN-UMIN000020766 {published data only}

* JPRN-UMIN000019181. Fecal microbiota transplantation for *Clostridium difficile* infection. trialssearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000020766 (first received 27 January 2016).

Kao 2017 {published data only}

Kao D, Roach B, Beck P, Hotte N, Madsen K, Louie T. A dual center, randomized trial comparing colonoscopy and oral capsule delivered fecal microbiota transplantation in the treatment of recurrent *Clostridium difficile* infection: preliminary results. *American Journal of Gastroenterology* 2015;**110**:S553.

Kao D, Roach B, Hotte N, Silva M, Madsen K, Beck P, et al. A prospective, dual center, randomized trial comparing colonoscopy versus capsule delivered fecal microbiota transplantation in the management of recurrent *Clostridium difficile* infection. *Canadian Journal of Gastroenterology and Hepatology* 2016;**318**(20):71-2.

* Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent *Clostridium difficile* infection a randomized clinical trial. *Journal of the American Medical Association* 2017;**318**(20):1985-93.

Kates 2020 {published data only}

* Kates AE, Gaulke I, De Wolfe T, Zimbric M, Haight K, Watson L, et al. Fecal microbiota transplantation for patients on antibiotic treatment with *C. difficile* infection history (GRAFT): study protocol for a phase II, randomized, double-blind, placebo-controlled trial to prevent recurrent *C. difficile* infections. *Contemporary Clinical Trials Communications* 2020;**18**:6. [DOI: [10.1016/j.conctc.2020.100576](https://doi.org/10.1016/j.conctc.2020.100576)]

NCT03621657. The GRAFT study: gut recolonization by fecal transplantation (GRAFT) [A phase II randomized, double-blind placebo-controlled trial to determine if fecal microbiota transplantation is efficacious for hospitalized patients with *C. difficile* infection history during antibiotic treatment]. clinicaltrials.gov/ct2/show/NCT03621657 (first received 8 august 2018). [NATIONAL CLINICAL TRIAL NUMBER: NCT03621657]

Lee 2016 {published data only}

* Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent *Clostridium difficile* infection a randomized clinical trial. *Journal of the American Medical Association* 2016;**315**(2):142-9. [DOI: [10.1001/jama.2015.18098](https://doi.org/10.1001/jama.2015.18098)]

Lee 2019 {published data only}

* Lee CH, Chai J, Hammond K, Jeon SR, Patel Y, Goldeh C, et al. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory *Clostridioides difficile* infection with or without antibiotic exposure. *European Journal of Clinical Microbiology & Infectious Diseases* 2019;**38**:1731-5. [DOI: [10.1007/s10096-019-03602-2](https://doi.org/10.1007/s10096-019-03602-2)]

Martinez 2018 {published data only}

* Martinez C, Edwards J, Hassoun A. Commercialized fecal microbiota transplantation provides efficacious treatment of *Clostridium difficile* infection. *Infectious Diseases* 2018;**50**(11-2):864-7. [DOI: [10.1080/23744235.2018.1500709](https://doi.org/10.1080/23744235.2018.1500709)]

NCT01398969 {published data only}

NCT01398969. Multi-centre trial of fresh vs. frozen-and-thawed FMT for recurrent CDI. clinicaltrials.gov/ct2/show/NCT01398969 (first received 11 July 2011). [NATIONAL CLINICAL TRIAL NUMBER: NCT01398969]

NCT01704937 {published data only}

NCT01704937. Fecal microbiota transplant (FMT) for relapsing *C. difficile* infection in adults and children using a frozen

inoculum. clinicaltrials.gov/ct2/show/NCT01704937 (first received 12 October 2012). [NATIONAL CLINICAL TRIAL NUMBER: NCT01704937]

NCT02254811 {published data only}

NCT02254811. FMT delivered by capsule versus colonoscopy for recurrent *C. diff* [A prospective, multi-center, randomized trial of fecal microbiota transplantation (FMT) delivered by capsule vs colonoscopy in the management of recurrent *Clostridium difficile* infection (CDI)]. clinicaltrials.gov/ct2/show/NCT02254811 (first received 2 October 2014). [NATIONAL CLINICAL TRIAL NUMBER: NCT02254811]

NCT02318992 {published and unpublished data}

NCT02318992. Fresh, frozen or lyophilized fecal microbiota transplantation for multiple recurrent *C. difficile* associated diarrhea. clinicaltrials.gov/ct2/show/NCT02318992 (first received 18 December 2014). [NATIONAL CLINICAL TRIAL NUMBER: NCT02318992]

NCT03298048 {published and unpublished data}

NCT03298048. Dose ranging study of the safety and efficacy of orally administered lyophilized fecal microbiota product (PRIM-DJ2727) for the treatment of recurrent *Clostridium difficile* infection (Cdi). clinicaltrials.gov/ct2/show/NCT03298048 (first received 29 September 2017). [NATIONAL CLINICAL TRIAL NUMBER: NCT03298048]

NCT03427229 {published data only}

NCT03427229. Fecal microbiota transplantation for severe *Clostridium difficile* infection [Randomized clinical trial: single versus multiple-infusion fecal microbiota transplantation for severe *Clostridium difficile* infection]. clinicaltrials.gov/ct2/show/NCT03427229 (first received 9 February 2018). [NATIONAL CLINICAL TRIAL NUMBER: NCT03427229]

NCT03804736 {published data only}

NCT03804736. Fecal microbiota transplant by oral capsules enriched with Lactobacilli for recurrent *Clostridium difficile* infection. clinicaltrials.gov/ct2/show/NCT03804736 (first received 15 January 2019). [NATIONAL CLINICAL TRIAL NUMBER: NCT03804736]

Satokari 2015 {published data only}

Satokari R, Mattila E, Kainulainen V, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent *Clostridium difficile* infection – an observational cohort study. *Alimentary Pharmacology & Therapeutics* 2015;**41**(1):46-53. [DOI: [10.1111/apt.13009](https://doi.org/10.1111/apt.13009)]

Youngster 2014 {published data only}

* Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing *Clostridium difficile* infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. *Clinical Infectious Diseases* 2014;**58**(11):1515-22. [DOI: [10.1093/cid/ciu135](https://doi.org/10.1093/cid/ciu135)]

References to studies awaiting assessment

Dubberke 2018 {published data only}

Dubberke ER, Lee C, Orenstein R, Khanna S, Hecht G, Fraiz J. Efficacy and safety of RBX2660 for the prevention of recurrent *Clostridium difficile* infection: results of the PUNCH CD 2 trial. *Open Forum Infectious Diseases* 2016;**3**(Suppl 1):1341. [DOI: [10.1093/ofid/ofw172.1044](https://doi.org/10.1093/ofid/ofw172.1044)]

* Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results from a randomized, placebo-controlled clinical trial of a RBX2660 – a microbiota-based drug for the prevention of recurrent *Clostridium difficile* infection [A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent *Clostridium Difficile* Infection]. *Clinical Infectious Diseases* 2018;**67**(8):1198-204. [DOI: [10.1093/cid/ciy259](https://doi.org/10.1093/cid/ciy259)]

Hecht GA, Orenstein R, Dubberke ER, Lee C, Khanna S. Lack of association with patient demographics and outcomes in PUNCH CD2, a randomized controlled trial of RBX2660, a microbiota-based drug for recurrent *Clostridium difficile* infection. *American Gastroenterological Association Abstracts* 2017;**152**(5):S951-2. [DOI: [10.1016/S0016-5085\(17\)33238-9](https://doi.org/10.1016/S0016-5085(17)33238-9)]

NCT02299570. Microbiota restoration therapy for recurrent *Clostridium difficile* infection (Punchcd2) [A phase 2b prospective, randomized, double-blinded, placebo-controlled clinical study demonstrating the efficacy and safety of Rebiotix RBX2660 (microbiota suspension) for the treatment of recurrent *Clostridium difficile* infection]. clinicaltrials.gov/ct2/show/NCT02299570 (first received 24 November 2014). [NATIONAL CLINICAL TRIAL NUMBER: NCT02299570]

Ramesh MS, Khanna S, Messer J, Adams M. Durable prevention of recurrent *C. difficile* infection with RBX2660: results of the PUNCH CD 2 trial. *American Journal of Gastroenterology* 2016;**111**:S93.

Kao 2019 {published data only}

Kao DH, Roach B, Walter J, Loebenberg R, Wong K. Effect of lyophilized sterile fecal filtrate vs lyophilized donor stool on recurrent *Clostridoides difficile* infection: preliminary results from a randomized, double-blind pilot study. *American Gastroenterological Association Abstracts* 2019;**156**(6):S-900.

NCT03353506 {published data only}

NCT03353506. Lyophilized fecal transplant vs lyophilized fecal filtrate in recurrent *C diff* infection [A prospective double blind randomized pilot study comparing the efficacy of lyophilized fecal microbiota transplantation (FMT) to lyophilized sterile fecal filtrate in the management of recurrent *Clostridium difficile* infection (CDI)]. clinicaltrials.gov/ct2/show/NCT03353506 (first received 27 November 2017). [NATIONAL CLINICAL TRIAL NUMBER: NCT03353506]

NCT03548051 {unpublished data only}

NCT03548051. Safety and efficacy of FMT in individuals with one or more recurrences of *Clostridium difficile* associated disease (CDAD) [Phase 1/2 placebo controlled, partially-blinded clinical trial to assess the safety and efficacy of microbial restoration by enema with banked and thawed processed stool in individuals

with one or more recurrences of *Clostridium difficile* associated disease (CDAD)]. clinicaltrials.gov/ct2/show/NCT03548051 (first received 6 June 2018).

References to ongoing studies

Drekonja 2021 {published data only}

Drekonja DM, Shaukat A, Zhang JH, Reinink AR, Nugent S, Dominitz JA, et al. Microbiota or placebo after antimicrobial therapy for recurrent *Clostridioides difficile* at home: a clinical trial with novel home-based enrollment. *Clinical Trials* 2021;**18**(5):622-9. [DOI: [10.1177/17407745211021198](https://doi.org/10.1177/17407745211021198)]

EUCTR2015-003062-82-DK {published data only}

EUCTR2015-003062-82-DK. Rectal bacteriotherapy, faecal microbiota transplantation or oral vancomycin for the treatment of recurrent *Clostridium difficile* infection: a randomised controlled trial. clinicaltrialsregister.eu/ctr-search/trial/2015-003062-82/DK (first received 11 January 2016).

NCT02255305 {unpublished data only}

NCT02255305. FMT versus antimicrobials for initial treatment of recurrent CDI [Fecal microbiota transplantation versus standard medical therapy for initial treatment of recurrent *Clostridium difficile* infection]. clinicaltrials.gov/ct2/show/NCT02255305 (first received 2 October 2014).

NCT02774382 {unpublished data only}

NCT02774382. Rectal bacteriotherapy, fecal microbiota transplantation or oral vancomycin treatment of recurrent *Clostridium difficile* infections. clinicaltrials.gov/ct2/show/NCT02774382 (first received 17 May 2016).

NCT03005379 {published and unpublished data}

NCT03005379. Microbiota or placebo after antimicrobial therapy for recurrent *C. difficile* at home (MATCH). clinicaltrials.gov/ct2/show/NCT03005379 (first received 29 December 2016).

NCT03053505 {unpublished data only}

NCT03053505. A novel faecal microbiota transplantation system for treatment of primary and recurrent *Clostridium difficile* infection (FMTREAT) [Two-arm, interventional, prospective, open-label, multi-center trial to evaluate the safety & effectiveness of FMT for treatment of adult patients with primary or recurrent CDI, using a novel, standardized microbiota transplantation system]. clinicaltrials.gov/ct2/show/NCT03053505 (first received 15 February 2017).

NCT03806803 {unpublished data only}

NCT03806803. Multicentre blinded comparison of lyophilized sterile fecal filtrate to lyophilized fecal microbiota transplant in recurrent *Clostridioides difficile* infection [A multicenter double blind randomized study comparing the efficacy of lyophilized sterile fecal filtrate to lyophilized fecal microbiota transplantation (FMT) in the management of recurrent *Clostridioides difficile* infection (CDI)]. clinicaltrials.gov/ct2/show/NCT03806803 (first received 16 January 2019). [NATIONAL CLINICAL TRIAL NUMBER: NCT03806803]

NCT03970200 {published and unpublished data}

NCT03970200. PMT for severe-CDI [A phase II, randomized trial to evaluate the safety and efficacy of fecal microbiota transplantation using the Penn microbiome therapy products for severe or severe-complicated/fulminant *Clostridium difficile* infection]. clinicaltrials.gov/ct2/show/NCT03970200 (first received 16 January 2020).

NCT04885946 {unpublished data only}

NCT04885946. Fecal microbiota transplantation for early *Clostridioides difficile* infection (EarlyFMT). clinicaltrials.gov/ct2/show/NCT04885946 (first received 12 May 2021).

NCT04960306 {unpublished data only}

NCT04960306. Fecal filtrate as a treatment option of multiple recurrent *Clostridioides difficile* infection (FILTRATE) [Fecal filtrate versus conventional microbiota transplantation in the treatment of multiple recurrent *Clostridioides difficile* infection (FILTRATE): a protocol of a randomized, controlled trial]. clinicaltrials.gov/ct2/show/NCT04960306 (first received 13 July 2021).

NCT05077085 {unpublished data only}

NCT05077085. Bezlotoxumab versus FMT for multiple recurrent CDI (BSTEP) [New treatment strategy for patients with multiple recurrent *Clostridioides difficile* infection with bezlotoxumab as first option]. clinicaltrials.gov/ct2/show/NCT05077085 (first received 13 October 2021).

NCT05201079 {unpublished data only}

NCT05201079. Recurrent *Clostridioides difficile* infection treatment with capsules of lyophilised faecal microbiota vs fidaxomicin [A randomised, controlled, open-label phase III clinical trial in patients with recurrent *Clostridioides difficile* (CD) infection, to evaluate the efficacy and safety of capsules of lyophilised faecal microbiota vs fidaxomicin]. clinicaltrials.gov/ct2/show/NCT05201079 (first received 21 January 2022).

NCT05266807 {unpublished data only}

NCT05266807. Fecal microbiota transplantation versus vancomycin or fidaxomicin in *Clostridioides difficile* infection first recurrence (FENDER) [Fecal microbiota transplantation versus vancomycin or fidaxomicin in *Clostridioides difficile* infection first recurrence: a randomized controlled, open-label, multicenter phase III clinical trial]. clinicaltrials.gov/ct2/show/NCT05266807 (first received 4 March 2022).

Additional references

Abu-Sbeih 2019

Abu-Sbeih H, Ali FS, Wang Y. Clinical review on the utility of fecal microbiota transplantation in immunocompromised patients. *Current Gastroenterology Reports* 2019;**21**(4):8.

ACG Clinical Guidelines 2021

Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of *Clostridioides difficile* infections. *American Journal of Gastroenterology* 2021;**116**(6):1124-47.

Al Momani 2018

Al Momani LA, Abughanimeh O, Boonpheng B, Gabriel JG, Young M. Fidaxomicin vs vancomycin for the treatment of a first episode of *Clostridium difficile* infection: a meta-analysis and systematic review. *Cureus Journal of Medical Science* 2018;**10**(6):e2778.

Alang 2015

Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. *Open Forum Infectious Diseases* 2015;**2**(1):ofv004.

Bakken 2011

Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating *Clostridium difficile* infection with fecal microbiota transplantation. *Clinical Gastroenterology and Hepatology* 2011;**9**(12):1044-9.

Balsells 2019

Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of *Clostridium difficile* infections: a systematic review and meta-analysis. *Journal of Global Health* 2019;**9**(1):010407.

Baunwall 2020

Baunwall SM, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, et al. Faecal microbiota transplantation for recurrent *Clostridioides difficile* infection: an updated systematic review and meta-analysis. *EClinicalMedicine* 2020;**23**(29-30):100642.

Cammarota 2017

Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* 2017;**66**(4):569-80.

CDC 2019

US Department of Health and Human Services, CDC. Antibiotic resistance threats in the United States, 2019. [cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf](https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf) (accessed prior to 19 January 2023).

Chang 2008

Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal microbiome in recurrent *Clostridium difficile*-associated diarrhea. *Journal of Infectious Diseases* 2008;**197**(3):435-8.

Covidence [Computer program]

Covidence. Version accessed 15 December 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.

Crobach 2018

Crobach MJ, Vernon JJ, Loo VG, Kong LY, Péchiné S, Wilcox MH, et al. Understanding *Clostridium difficile* colonization. *Clinical Microbiology Reviews* 2018;**31**(2):e00021-17.

Davidovics 2019

Davidovics ZH, Michail S, Nicholson MR, Kociolek LK, Pai N, Hansen R, et al. Fecal microbiota transplantation for recurrent *Clostridium difficile* infection and other conditions in children:

a joint position paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. *Journal of Pediatric Gastroenterology and Nutrition* 2019;**68**(1):130-43.

Dembrowszky 2020

Dembrowszky F, Gede N, Szakács Z, Hegyi P, Kiss S, Farkas N, et al. Fecal microbiota transplantation may be the best option in treating multiple *Clostridioides difficile* infection: a network meta-analysis. *Infectious Diseases & Therapy* 2020;**10**:201-11.

Dethlefsen 2008

Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLOS Biology* 2008;**6**(11):e280.

Drekonja 2015

Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, et al. Fecal microbiota transplantation for *Clostridium difficile* infection: a systematic review. *Annals of Internal Medicine* 2015;**162**(9):630-8.

Dumville 2006

Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. *BMJ* 2006;**332**(7547):969-71.

FDA 2013

US Department of Health and Human Services, Food and Drug Administration: Center for Biologics Evaluation and Research. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat *Clostridium difficile* infection not responsive to standard therapies. [fda.gov/media/86440/download](https://www.fda.gov/media/86440/download) (accessed 12 March 2022).

FDA 2019

US Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. [fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse) (accessed 12 March 2022).

FDA 2020a

FDA. Fecal microbiota for transplantation: safety alert – risk of serious adverse events likely due to transmission of pathogenic organisms. [fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission](https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission) (accessed 12 March 2022).

FDA 2020b

FDA. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. [fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections) (accessed 12 March 2022).

Fekety 1993

Fekety R, Shah AB. Diagnosis and treatment of *Clostridium difficile* colitis. *JAMA* 1993;**269**(1):71-5.

Fekety 1997

Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent *Clostridium difficile* diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. *Clinical Infectious Diseases* 1997;**24**(3):324-33.

Gupta 2011

Gupta SK. Intention-to-treat concept: a review. *Perspectives in Clinical Research* 2011;**2**(3):109-12.

Guyatt 2011

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. Introduction – GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology* 2011;**64**(4):383-94.

Higgins 2020

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.

Hui 2019

Hui W, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent *C. difficile* infection: an updated randomized controlled trial meta-analysis. *PLOS One* 2019;**14**(1):e0210016.

Ianiro 2018

Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory *Clostridium difficile* infection – single versus multiple infusions. *Alimentary Pharmacology & Therapeutics* 2018;**48**(2):152-9.

Imdad 2018

Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, et al. Fecal transplantation for treatment of inflammatory bowel disease. *Cochrane Database of Systematic Reviews* 2018, Issue 11. Art. No: CD012774. [DOI: [10.1002/14651858.CD012774.pub2](https://doi.org/10.1002/14651858.CD012774.pub2)]

Jiang 2018a

Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent *Clostridium difficile* infection: a randomized clinical trial. *PLOS One* 2018;**13**(11):e0205064.

Johnsen 2018

Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-

group, single-centre trial. *Lancet Gastroenterology & Hepatology* 2018;**3**(1):17-24.

Kao 2017

Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent *Clostridium difficile* infection: a randomized clinical trial. *JAMA* 2017;**318**(20):1985-93.

Kassam 2013

Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. *American Journal of Gastroenterology* 2013;**108**(4):500-8.

Kellermayer 2019

Kellermayer R. Fecal microbiota transplantation: great potential with many challenges. *Translational Gastroenterology and Hepatology* 2019;**4**:40.

Kelly 2008

Kelly CP, LaMont JT. *Clostridium difficile* – more difficult than ever. *New England Journal of Medicine* 2008;**359**(18):1932-40.

Kelly 2014

Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of *Clostridium difficile* infection in immunocompromised patients. *American Journal of Gastroenterology* 2014;**109**(7):1065-71.

Kelly 2015

Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. *Gastroenterology* 2015;**129**(1):223-37.

Kelly 2021

Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry. *Gastroenterology* 2021;**160**(1):183-92.

Khan 2018

Khan MY, Dirweesh A, Khurshid T, Siddiqui WJ. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent *Clostridium difficile* infection: a systematic review and meta-analysis. *European Journal of Gastroenterology & Hepatology* 2018;**30**(11):1309-17.

Khanna 2017

Khanna S, Vazquez-Baeza Y, González A, Weiss S, Schmidt B, Muñoz-Pedrogo DA, et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent *C. difficile* infection affected by underlying inflammatory bowel disease. *Microbiome* 2017;**5**(1):55.

Kociolek 2016

Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of *Clostridium difficile* infection. *Nature Reviews Gastroenterology & Hepatology* 2016;**13**(3):150-60.

Lawson 2016

Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Prévot 1938. *Anaerobe* 2016;**40**:95-9.

Lee 2016

Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent *Clostridium difficile* infection: a randomized clinical trial. *JAMA* 2016;**315**(2):142-9.

Lefebvre 2022

Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.

Leffler 2015

Leffler DA, Lamont JT. *Clostridium difficile* infection. *New England Journal of Medicine* 2015;**372**(16):1539-48.

Lessa 2015

Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of *Clostridium difficile* infection in the United States. *New England Journal of Medicine* 2015;**372**(9):825-34.

Link 2016

Link A, Lachmund T, Schulz C, Weigt J, Malfertheiner P. Endoscopic peroral jejunal fecal microbiota transplantation. *Digestive & Liver Disease* 2016;**48**(11):1136-9.

McDonald 2007

McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kuty PK, Ad Hoc *Clostridium difficile* Surveillance Working Group. Recommendations for surveillance of *Clostridium difficile*-associated disease. *Infection Control & Hospital Epidemiology* 2007;**28**(2):140-5.

McDonald 2018

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clinical Infectious Diseases* 2018;**66**(7):987-94.

MS Excel 2018 [Computer program]

Microsoft Excel. Microsoft Corporation, 2018. Available from office.microsoft.com/excel.

Mullish 2018

Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Gut* 2018;**67**(11):1920-41.

Petersen 2014

Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. *Cellular Microbiology* 2014;**16**(7):1024-33.

Pomares Bascuñana 2021

Pomares Bascuñana RÁ, Veses V, Sheth CC. Effectiveness of fecal microbiota transplant for the treatment of *Clostridioides difficile* diarrhea: a systematic review and meta-analysis. *Letters in Applied Microbiology* 2021;**73**(2):149-58.

Quraishi 2017

Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory *Clostridium difficile* infection. *Alimentary Pharmacology & Therapeutics* 2017;**46**(5):479-93.

Ramai 2021

Ramai D, Zakhia K, Fields PJ, Ofosu A, Patel G, Shahnazarian V, et al. Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent *Clostridioides difficile* infection: a systematic review and meta-analysis. *Digestive Diseases and Sciences* 2021;**66**(2):369-80.

Razik 2016

Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of *Clostridium difficile* infection in patients with inflammatory bowel disease: the RECIDIVISM study. *American Journal of Gastroenterology* 2016;**111**(8):1141-6.

Red Book 2018

American Academy of Pediatrics. *Clostridium difficile*. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors(s). *Red Book: 2018 Report of the Committee on Infectious Diseases*. 31st edition. Itasca (IL): American Academy of Pediatrics, 2018:288-92.

Review Manager 2014 [Computer program]

Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

RevMan Web 2020 [Computer program]

Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.

Rokkas 2019

Rokkas T, Gisbert JP, Gasbarrini A, Hold GL, Tilg H, Malfertheiner P, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent *Clostridium difficile* infection. *United European Gastroenterology Journal* 2019;**7**(8):1051-63.

Saha 2021

Saha S, Mara K, Pardi DS, Khanna S. Long-term safety of fecal microbiota transplantation for recurrent *Clostridioides difficile* infection. *Gastroenterology* 2021;**160**(6):1961-9.

Shannon-Lowe 2010

Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of *Clostridium difficile* infection. *BMJ* 2010;**340**:c1296.

Solari 2014

Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal transplant. *Clinical Infectious Diseases* 2014;**59**(2):319.

Sterne 2019

Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;**28**(366):l4898.

Vardakas 2012

Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of *Clostridium difficile* infection following treatment with vancomycin

or metronidazole: a systematic review of the evidence. *International Journal of Antimicrobial Agents* 2012;**40**(1):1-8.

Woodworth 2017

Woodworth MH, Neish EM, Miller NS, Dhert T, Burd EM, Carpentieri C, et al. Laboratory testing of donors and stool samples for fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Journal of Clinical Microbiology* 2017;**55**(4):1002-10.

References to other published versions of this review
Imdad 2021

Imdad A, Minkoff NZ, Tanner-Smith EE, Zackular JP, Acra S, Nicholson MR. Fecal microbiota transplantation for the treatment of recurrent *Clostridioides difficile* (*Clostridium difficile*). *Cochrane Database of Systematic Reviews* 2021, Issue 2. Art. No: CD013871. [DOI: [10.1002/14651858.CD013871](https://doi.org/10.1002/14651858.CD013871)]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]

Cammarota 2015
Study characteristics

Methods	Single center, open-label, randomized controlled clinical trial conducted in Italy
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> Age \geq 18 years Life expectancy \geq 3 months Relapse of CDI after \geq 1 courses of specific antibiotic therapy (\geq 10 days of vancomycin \geq 125 mg 4 times daily or \geq 10 days of metronidazole 500 mg 3 times a day) Able to undergo colonoscopy <p>Exclusion criteria</p> <ol style="list-style-type: none"> Immunosuppressed; recent chemotherapy, HIV infection, prolonged use of steroids Pregnancy Antibiotics used other than metronidazole, vancomycin, and fidaxomicin at baseline ICU admission or vasopressor use Other infectious causes of diarrhea
Interventions	<p>Intervention</p> <p>Fresh donor feces solution infusion after pretreatment with vancomycin for 3 days and bowel lavage 1 or 2 days before FMT; n = 20</p> <p>Route: colonoscopy</p> <p>Frequency: every 3 days if the participant had pseudomembranous colitis until resolution</p> <p>Weight of stool: mean 152 g</p> <p>Volume per treatment: 500 mL</p>

Cammarota 2015 (Continued)

Donor: healthy relative or unrelated volunteers

Comparison

Standard vancomycin 125 mg orally 4 times daily for 10 days, followed by a pulse regimen (125–500 mg/day every 2–3 days) for ≥ 3 weeks; n = 19

Donor screening

1. Healthy adults (aged < 50 years) preferably relative or intimates were screened for fecal donation using a questionnaire addressing risk factors for potentially transmissible diseases (antibiotics in last 6 months, new sexual relations in the last 6 months, history of tattoos, needle stick injury, blood transfusion, personal or family history of GI disease)
2. Donor feces were screened for parasites, *C difficile*, and enteropathogenic bacteria (VRE, MRSA, and gram-negative MDR)
3. Blood was screened for hepatitis A, B, and C; antibodies to HIV-1 and HIV-2; EBV; *Treponema pallidum*; *Strongyloides stercoralis*; and *Entamoeba histolytica*
4. Before donation, another questionnaire was used to screen for recent illnesses

Outcomes
Primary outcome

1. Resolution of diarrhea associated with *C difficile* infection (disappearance of diarrhea, or persistent diarrhea explicable by other causes, with 2 negative stool tests for *C difficile* toxin) 10 weeks after end of treatments. For participants in FMT group who required > 1 infusion of feces, follow-up was extended to 10 weeks after the last infusion.

Secondary outcome

1. Toxin negative without recurrent *C difficile* infection (diarrhea unexplainable by other causes, with or without positive stool toxin) 5 weeks and 10 weeks after end of treatments.

Notes

Recurrence after treatment was defined as diarrhea (≥ 3 loose or watery stools per day for ≥ 2 consecutive days, or ≥ 8 loose stools in 48 hours) unexplainable by other causes, with or without positive stool toxin within 10 weeks from end of therapy. This is different from a recurrence of new CDI per our protocol.

The authors performed analysis on an intention-to-treat basis.

The trial was stopped 1 year earlier.

Funding: (quote) "The study was in part funded by the Catholic University of Rome, Line D-1 research funding".

Hota 2017
Study characteristics
Methods

Single-site, open-label, randomized controlled trial conducted in Canada

Participants
Inclusion criteria

1. Aged ≥ 18 years
2. History of ≥ 2 episodes of laboratory (*C difficile* toxin EIA or PCR) or pathology-confirmed CDI
3. Received ≥ 1 course of oral vancomycin (minimum 10 days of 500 mg total daily dose)
4. Having symptoms correlating with CDI infection that were self-reported and confirmed by study physicians to meet standard epidemiologic definitions of diarrhea

Exclusion criteria

Hota 2017 (Continued)

1. Neutropenia, graft versus host disease or other severe immunocompromised states
2. CDI requiring ICU admission
3. Active, severe colitis unresponsive to oral vancomycin
4. Hypersensitivity or intolerance to oral vancomycin
5. Chronic GI diseases that may cause diarrhea
6. Planned therapy in the next 120 days that may cause diarrhea (e.g. chemotherapy) or planned surgery requiring perioperative antibiotics within 120 days
7. Pregnancy
8. Significant bleeding disorder
9. Inability to tolerate FMT procedure

Interventions

Intervention

Fresh donor feces solution enema given 48 hours after pretreatment with vancomycin for 14 days; n = 16

Route: enema

Frequency: single

Weight of stool: 50 g

Volume per treatment: 500 mL

Donor: healthy relative or unrelated volunteers

Comparison

Vancomycin 14 days of standard dosing (125 mg orally every 6 hours) followed by a taper over 4 weeks; n = 14

Donor screening

Healthy adult aged ≥ 18 years screened using a self-screening questionnaire of behaviors associated with risk for blood-borne pathogens, study physician assessment, and blood and stool testing for potentially transmissible infections and screening were developed in consultation with Health Canada.

Outcomes

Primary outcome

1. Recurrence of symptomatic, laboratory-confirmed CDI within 120 days of the intervention

Secondary outcomes

1. Recurrence of CDI symptoms within 14 and 120 days (not laboratory-confirmed)
2. Recurrence of CDI within 120 days of crossover
3. Days of diarrhea in the 120 days of follow-up
4. CDI requiring hospital admission

Safety outcomes

1. Solicited AEs at days 4 and 7
2. Unsolicited AEs within 14 days of interventions
3. SAEs throughout follow-up
4. Mortality attributable to CDI during follow-up
5. All-cause mortality throughout follow-up

Notes

Recurrence was described as symptomatic, laboratory-confirmed CDI within 120 days of the intervention and this is different from recurrence of new CDI per our protocol.

Hota 2017 (Continued)

The study authors performed a per-protocol analysis. We created an intention-to-treat analysis by considering all the participants who were randomized to FMT and vancomycin group. We also performed a sensitivity analysis on an as-available basis.

The authors reported lack of resolution of rCDI and our primary outcome was resolution of rCDI. We subtracted the ones whose rCDI did not resolve from the total randomized to obtain the participants with resolution of rCDI.

Funding for the study: (quote) "This work was supported by the Physicians Services Incorporated Foundation (grant number PSI 10-2021); Public Health Ontario; University of Toronto Department of Medicine Integrating Challenge Grant; University Health Network; and Sinai Health System (in kind)."

Hvas 2019
Study characteristics

Methods	Single center, randomized, active-comparator, open-label clinical trial conducted in Denmark
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Aged ≥ 18 years 2. Diarrhea; ≥ 3 more liquid stools (Bristol 6–7) per day 3. Positive PCR test result for <i>C difficile</i> toxin A, toxin B, or binary toxin 4. Recurrent CDI and documented recurrence within 8 weeks after stopping anti-CDI treatment 5. ≥ 1 prior treatment course with vancomycin or fidaxomicin for CDI <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Pregnant or breastfeeding 2. Inability to speak or understand the Danish language 3. Ongoing antibiotic treatment 4. Use of drugs with a known interaction with vancomycin or fidaxomicin, allergy to either study drug 5. Fulminant colitis that contraindicated medical treatment 6. If the treating physician decided the person would be unable to tolerate the treatment
Interventions	<p>Intervention</p> <p>Frozen-thawed single-donor solution of donor feces was applied after pretreatment with vancomycin for 4–10 days and bowel lavage 1 or 2 days before FMT; n = 24</p> <p>Route: nasoduodenal or colonoscopy (depending on tolerance)</p> <p>Frequency: up to 2 times if needed</p> <p>Weight of stool: 50 g</p> <p>Volume per treatment: –</p> <p>Donor: healthy unrelated volunteer</p> <p>Comparison (2 groups)</p> <ol style="list-style-type: none"> 1. Fidaxomicin 200 mg 2 times daily for 10 days; n = 24 2. Vancomycin 125 mg 4 times daily for 10 days; n = 16 <p>Donor screening</p>

Hvas 2019 (Continued)

1. Consenting voluntary recruited at the public blood center, approached in person during the time of donating blood or plasma
2. Fulfilled all criteria to donate blood
3. Screening program; electronic questionnaire that addressed GI complaints, risk behavior, and diet
4. Those eligible progressed to a screening of blood and feces
5. Consultation with a gastroenterologist to formally become active feces donors

Recurrence was described as clinical relapse and a positive *C difficile* test result before or at 8 weeks after the allocated treatment, this is different from recurrence of new CDI per our protocol.

Outcomes
Primary outcome

1. Combined clinical resolution and a negative *C difficile* test result without the need for rescue FMT or colectomy 8 weeks after the initial treatment.

Secondary outcome

1. Clinical resolution at week 8, a negative CD test result at week 8, combined clinical resolution and negative CD test result at week 1, clinical resolution at week 1, and a negative CD test result at week 1

Safety outcomes

1. AEs
2. SAEs
3. Immediate complications in 24 hours

Notes

The study author performed an intention-to-treat analysis.

For our analysis, we used the total of the 2 comparison groups as the single control group (fidaxomicin + vancomycin).

Authors reported resolution of rCDI based on 2 definitions. We included the definition based on resolution of diarrhea + negative test for *Cdifficile*

The data on serious adverse events were taken from the supplementary document.

Funding: (quote) "This study was financed by the Danish Regions (grant 14/217). The funder had no access to the data and had no influence on the study presentation."

Kelly 2016
Study characteristics
Methods

Dual-center, double-blind, randomized controlled trial conducted in the US

Participants
Inclusion criteria

1. Adults
2. ≥ 3 documented CDI recurrences
3. Did not maintain cure after a course of tapered or pulsed vancomycin or were unable to taper or discontinue vancomycin without recurrent diarrhea (or an alternative antibiotic with activity against CDI)
4. Completed ≥ 10 days of vancomycin therapy for the most recent CDI and continued therapy until 2–3 days before the intervention

Exclusion criteria

Kelly 2016 (Continued)

1. Aged \geq 75 years
2. History of inflammatory bowel disease, irritable bowel disease, or chronic diarrheal disorder
3. Immunocompromised state or immunodeficiency
4. Anaphylactic food allergy
5. Previous FMT
6. Untreated in situ colorectal cancer
7. Inability to undergo colonoscopy

Interventions
Intervention

Fresh donor feces solution infusion after bowel lavage the day before FMT; n = 22

Route: colonoscopy

Frequency: single

Weight of stool: mean 64 g

Volume per treatment: 500 mL

Donor: healthy relative or unrelated volunteers screened using questionnaires, and blood and stool laboratory testing.

Comparison

Autologous feces solution infusion after bowel lavage the day before FMT; n = 24

Donor screening

1. Medical interview and physical exam to exclude communicable disease, features of the metabolic syndrome, diarrheal disorder, autoimmune or atopic disease, tumor, neurologic disorder, or chronic pain syndrome or antibiotics use for any indication within 3 months
2. Modified AABB full-length donor history questionnaire, and those with risk factors for infectious agents were excluded
3. Serologic and stool testing 1 month prior to donation for FMT; hepatitis A, B, and C viruses; *Treponema pallidum*; *C difficile* toxin PCR; culture for enteric pathogens (*Escherichia coli*, Salmonella, Shigella, Yersinia, Campylobacter, *Listeria monocytogenes*, *Vibrio parahaemolyticus*, and *V cholerae*); fecal Giardia and Cryptosporidium antigens; acid-fast stain for detection of Cyclospora and Isospora; ova and parasite testing; and EIA for detection of Rotavirus
4. HIV-1 and HIV-2 testing within 2 weeks before the donation

Outcomes
Primary outcome

1. Clinical cure 8 weeks after FMT or at the time of early withdrawal. Clinical cure defined as resolution of diarrhea (i.e. $<$ 3 unformed stools for 2 consecutive days), with maintenance of resolution for 8-week follow-up period and no further requirements for anti-infective therapy for *C difficile* infection regardless of results of follow-up stool testing for *C difficile*

Secondary outcome

1. Clinical failure during the 8-week period after FMT. Clinical failure defined as the persistence or development of diarrhea and the need for additional anti-infective therapy for CDI with or without positive stool testing (PCR) for *C difficile*

Safety endpoints

1. SAEs
2. AEs
3. Death
4. New medical conditions or diagnoses, or changes in medical conditions at 6-month follow-up

Kelly 2016 (Continued)

Notes	<p>Study authors described late CDI recurrence as after 8 weeks, which is similar to the recurrence of new CID per our protocol.</p> <p>Study authors performed analysis on an intention-to-treat basis. We also recreated the analysis on an as-available basis taking into account any missing data.</p> <p>Funding: National Institute of Diabetes and Digestive and Kidney Diseases</p>
-------	---

Rode 2021
Study characteristics

Methods	Open-label, multicenter randomized controlled trial conducted in Denmark
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Aged ≥ 18 years 2. Recurrence of <i>C difficile</i> infection, i.e. diarrhea and a new positive test for <i>C difficile</i> within 90 days after a former episode of CDI 3. Has received ≥ 1 course of either vancomycin (≥ 125 mg 4 times daily for 10 days) or metronidazole (≥ 500 mg 3 times daily for 10 days) 4. Possibly have started oral vancomycin within 7 days prior to inclusion 5. Ability to give informed consent <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Life expectancy < 3 months 2. Allergy to vancomycin 3. Other GI diseases, infections, and conditions with diarrhea or disturbed symptom reporting, such as colectomy 4. Planned concomitant antibiotic treatment for > 14 days after inclusion 5. Severe immune suppression 6. Pregnancy, breastfeeding women, fertile women with no reliable birth control
Interventions	<p>Intervention</p> <p>Frozen-thawed donor feces solution given 36 hours after pretreatment with vancomycin for 1–14 days; n = 34</p> <p>Route: enema</p> <p>Frequency: 1–3 infusions</p> <p>Weight of stool: 50 g</p> <p>Volume per treatment: 170 mL</p> <p>Donor: healthy relative or unrelated volunteers</p> <p>Comparison</p> <ol style="list-style-type: none"> 1. Vancomycin 125 mg 4 times daily for 14 days. Participants with ≥ 2 recurrences of CDI were treated with additional 5 weeks of vancomycin taper; n = 31 2. RBT; 12 bacterial strains suspended in 200 mL isotonic saline given via enema 12 hours after pre-treatment with vancomycin for 7–12 days. 3 infusions were given on 3 consecutive days; n = 33 <p>Donor screening</p>

Rode 2021 (Continued)

Used frozen donor stool from a donor stool bank with extensively tested universal donors recruited from the Danish Blood Donor Corps.

Outcomes

Primary outcome

1. Clinical cure within 90 days after ended treatment. Clinical cure defined as absence of *C difficile* infection (i.e. absence of diarrhea or diarrhea with a negative *C difficile* test)

Secondary outcome

1. Clinical cure within 180 days after ended treatment

Safety outcomes

1. AEs
2. SAEs
3. 180-day mortality (all-cause and possibly *C difficile*-related mortality)

Notes

Study authors did not comment on the recurrence of a new CDI.

Study authors analyzed the primary endpoint on intention-to-treat, modified intention-to-treat, and per-protocol basis. We added both intention-to-treat and as-available analysis for primary outcomes to the review.

For our analysis, we used the total of the 2 comparison groups as the control.

Funding: (quote) "This study was funded by Ministeriet Sundhed Forebyggelse, The Research Council for Naestved/Ringste/Slagelse Hospital, Hvidovre Hospital, The Research fund of the Department of Infectious Disease, Hvidovre Hospital, The Christenson-Cesons Family Foundation and the Region Sjælland. None of the funders had any influence on designing the study, analysing data or writing the manuscript."

van Nood 2013
Study characteristics

Methods

Open-label, randomized controlled trial conducted in the Netherlands

Participants

Inclusion criteria

1. Aged ≥ 18 years
2. Life expectancy ≥ 3 months
3. Relapse of CDI after ≥ 1 episode of CDI appropriately treated ≥ 1 course of adequate antibiotics (≥ 10 days of vancomycin at a dose of ≥ 125 mg 4 times per day or ≥ 10 days of metronidazole 500 mg 3 times per day)

Exclusion criteria

1. Immunosuppressed; receiving chemotherapy, HIV positive with CD4 count < 240 cells/ μ L, prolonged use of prednisolone ≥ 60 g/day
2. Pregnancy
3. Use of antibiotics other than for treatment of *C difficile* infection at baseline
4. Admission to an ICU or need for vasopressor medication

Interventions

Intervention

Fresh donor feces solution infusion after pretreatment with vancomycin for 4–5 days and bowel lavage the day before FMT; n = 17

van Nood 2013 (Continued)

Route: nasoduodenal tube

Frequency: up to 2 times if needed

Weight of stool: mean 141 g

Volume per treatment: 500 mL

Donor: healthy unrelated volunteers

Comparison

1. Standard vancomycin regimen (500 mg orally 4 times per day for 14 days); n = 13
2. Standard vancomycin regimen + bowel lavage on day 4 or 5; n = 13

Donor screening

1. Healthy adults aged < 60 years. Volunteers were screened for fecal donation using questionnaire addressing risk factors for potentially transmissible diseases
2. Donor feces were screened for parasites (including *Blastocystis hominis* and *Dientamoeba fragilis*), *C difficile*, and enteropathogenic bacteria
3. Blood was screened for antibodies to HIV; human T-cell lymphotropic virus types 1 and 2; hepatitis A, B, and C; Cytomegalovirus; EBV; *Treponema pallidum*; *Strongyloides stercoralis*; and *Entamoeba histolytica*
4. A donor pool was created, and screening was repeated every 4 months
5. Before donation, another questionnaire was used to screen for recent illnesses

Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> 1. Cure without relapse within 10 weeks after initiation of therapy. If a patient required a second infusion of donor feces, follow-up was extended to 10 weeks after the second infusion for primary outcome assessment. Cure defined as absence of diarrhea or persistent diarrhea that could be explained by other causes with 3 consecutive negative stool tests for <i>C difficile</i> toxin <p>Secondary outcome</p> <ol style="list-style-type: none"> 1. Cure without relapse after 5 weeks. Relapse defined as diarrhea with a positive stool test for <i>C difficile</i> toxin
Notes	<p>Study authors performed analysis on a modified intention-to-treat basis with the exclusion of 1 participant who required high-dose prednisolone treatment after randomization but before the study treatment was initiated. We recreated an intention-to-treat analysis and also included an as-available analysis.</p> <p>For our analysis, we used the total of the 2 comparison groups as the control.</p> <p>Funding: (quote) "Supported by grants from the Netherlands Organization for Health Research and Development (ZonMW, 170881001; VENI grant, MN: 016096044) and a Spinoza Award (to Dr. de Vos) from the Netherlands Organization for Scientific Research."</p>

CDI: *Clostridioides difficile* infection; EBV: Epstein-Barr virus; EIA: enzyme immunoassay; FMT: fecal microbiota transplantation; GI: gastrointestinal; ICU: intensive care unit; MDR: multiple drug-resistant; MRSA: methicillin-resistant *Staphylococcus aureus*; n: number of participants; PCR: polymerase chain reaction; VRE: vancomycin-resistant enterococci.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Allegretti 2016	Wrong comparator; low- and high-dose FMT capsules.

Study	Reason for exclusion
Allegretti 2019	Wrong comparator; this is a comparison of FMT delivered via gastric release and targeted colonic release capsules
Cicerone 2017	Wrong comparator; full publication not available but seemed to not have a 'no FMT group' and, therefore, it would not qualify as a randomized controlled trial.
Dupont 2017	Wrong comparator; encapsulated lyophilized FM given once or on 2 successive days vs frozen FM product given by single retention enema.
Fischer 2015	Wrong comparator; low- and high-dose FMT capsules.
Friedman-Korn 2018	Wrong study design; prospective cohort observational study.
Garza-Gonzalez 2019	Wrong comparator; comparison of FMT vs FMT enriched with Lactobacillus.
Ianiro 2018	Wrong comparator; single-infusion FMT, including a vancomycin antibiotic regimen plus a single administration of feces by colonoscopy; or multiple-infusion FMT, including a vancomycin antibiotic regimen plus multiple fecal infusions.
Jiang 2017	Wrong comparator; comparison of fresh, frozen, and lyophilized FMT.
Jiang 2018b	Wrong comparator; comparison of lyophilized fecal microbiota vs frozen FMT.
Jiang 2018c	Wrong comparator; lower GI administration (retention enema with frozen product) versus upper GI route (oral administration of lyophilized product in enteric-coated capsules).
JPRN-UMIN000016900	Wrong study design; single arm non-randomized trial.
JPRN-UMIN000019181	Wrong study design; single arm non-randomized trial.
JPRN-UMIN000020766	Wrong study design; single arm non-randomized trial.
Kao 2017	Wrong comparator; FMT by oral capsule or colonoscopy at 1:1 ratio.
Kates 2020	Wrong indication; FMT was given to participant with prior history of CDI while on antibiotics to prevent recurrence of rCDI, not to treat rCDI.
Lee 2016	Wrong comparator; comparison of fresh vs frozen FMT.
Lee 2019	Wrong study design; retrospective study.
Martinez 2018	Wrong study design; observational study.
NCT01398969	Wrong comparator; fresh vs frozen-and-thawed FMT.
NCT01704937	Wrong comparator; FMT delivery by nasogastric tube or colonoscopy.
NCT02254811	Wrong comparator; delivery via capsules vs colonoscopy.
NCT02318992	Wrong comparator; comparison of fresh vs frozen vs lyophilized FMT.
NCT03298048	Wrong comparator; comparison of low- vs mid- vs high-dose FMT.
NCT03427229	Wrong comparator; aimed to assess if multiple-infusion FMT is more effective than single-infusion FMT in curing severe CDI.

Study	Reason for exclusion
NCT03804736	Wrong comparator; comparison of FMT vs FMT enriched with Lactobacillus
Satokari 2015	Wrong comparator; this is a comparison of fresh vs frozen feces for FMT and had no control group; also it was a retrospective non-randomized study.
Youngster 2014	Wrong comparator; comparison of FMT administered via colonoscopy vs nasogastric tube.

CDI: *Clostridioides difficile* infection; FM: fecal microbiota; FMT: fecal microbiota transplantation; GI: gastrointestinal; rCDI: recurrent *Clostridioides difficile* infection.

Characteristics of studies awaiting classification [ordered by study ID]

Dubberke 2018

Methods	Randomized, double-blind, placebo-controlled, phase 2b study
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Aged ≥ 18 years 2. Medical record documentation of rCDI either: ≥ 2 recurrences after a primary episode and has completed ≥ 2 rounds of standard-of-care oral antibiotic therapy or has had ≥ 2 episodes of severe CDI resulting in hospitalization 3. Documented history that the person's rCDI is controlled while on antibiotics even if the person is not currently on antibiotics 4. A positive stool test for the presence of <i>C difficile</i> within 60 days prior to enrollment <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. History of continued <i>C difficile</i> diarrhea while on a course of antibiotics prescribed for CDI treatment 2. Requires antibiotic therapy for a condition other than rCDI 3. Previous fecal transplant prior to study enrollment 4. History of inflammatory bowel disease 5. History of irritable bowel syndrome 6. History of chronic diarrhea 7. History of celiac disease 8. Colostomy 9. Planned surgery requiring perioperative antibiotics within 6 months of study enrollment 10. Life expectancy < 12 months 11. Compromised immune system
Interventions	<p>Intervention</p> <p>Group A: 2 enemas of RBX2660 (microbiota suspension) administered 7 days apart</p> <p>Group C: 1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo (a suspension of saline and cryoprotectant) administered 7 days apart</p> <p>Comparison</p> <p>Group B: 2 enemas of placebo (a suspension of saline and cryoprotectant) administered 7 days apart</p>
Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> 1. Treatment success of Group A versus Group B assessed at 8 weeks

Dubberke 2018 (Continued)

Secondary outcome

1. Treatment success between Group C versus Group B assessed at 8 weeks
2. Treatment success evaluated between Group A versus Group C assessed at 8 weeks
3. 36-item Short Form Health Survey (SF-36) scores obtained at 1, 4, and 8-week assessment visits during the double-blind period as compared to baseline assessed at 8 weeks
4. Time to CDAD recurrence after completion of the assigned study treatment for Group A versus Group B at 8 weeks
5. Time to CDAD recurrence after completion of the assigned study treatment for Group C versus Group B at 8 weeks
6. Time to CDAD recurrence after completion of the assigned study treatment for Group A versus Group C at 8 weeks

Notes

Based on the proprietary nature and our lack of access to procedures between the collection of donor stool and shipping of the RBX2660 microbiota suspension, it is unclear at the time of this publication whether the RBX2660 'microbiota suspension' technically qualifies as FMT per se. We will contact the study authors to request additional details and this study may qualify for inclusion in future versions of this systematic review and meta-analysis.

Kao 2019
Methods

Randomized, controlled, pilot study

Participants
Inclusion criteria

1. Age >18 years
2. Diagnosis of ≥ 3 episodes of rCDI, each episode defined by presence of diarrhea (≥ 3 unformed stools/24 hours), positive for *C difficile* toxin, episodes occurring within 2 months of each other after finishing anti-CDI therapy, and recurring diarrhea after symptom resolution following ≥ 10 days of anti-CDI therapy
3. CDI infection under symptomatic control with < 3 loose/unformed stools/24 hours for ≥ 2 consecutive days before treatment
4. Ability to provide informed consent

Exclusion criteria

1. Fulminant CDI
2. Chronic diarrheal illness
3. Taking or planning to take investigational drug within 3 months of enrollment
4. Dysphagia
5. Ileus or bowel obstruction
6. Pregnancy
7. Active infection requiring antibiotic therapy
8. Life expectancy < 6 months

Interventions
Intervention

Single dose of 15 capsules of lyophilized donor stool

Comparison

Single dose of 15 capsules of lyophilized sterile fecal filtrate

Outcomes
Primary outcome

1. Proportion of participants in each group with no CDI recurrence at week 8

Kao 2019 (Continued)

Secondary outcomes

1. Mortality rate at week 8
2. Infections directly attributable to CDI or treatment at week 8

Notes

While this study meets criteria and has been completed there was not enough information for us to complete the risk of bias assessment and include the data in the analysis.

NCT03353506

Methods

Double-blind, randomized, controlled, pilot study

Participants

Inclusion criteria

1. ≥ 3 episodes of recurrent CDI, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive *C difficile* toxin, each occurring within 3 months of each other.
2. CDI under symptomatic control with ≤ 3 unformed stools in 24 hours for ≥ 2 consecutive days prior to treatment
3. Ability to provide informed consent
4. Females and males must agree to use effective birth control for the duration of the study

Exclusion criteria

1. Complicated CDI defined as WBC $> 35,000$ cells/mL, significant abdominal pain and distention, evidence of toxin megacolon or pseudomembranous colitis, hypotension defined as systolic blood pressure < 90 mmHg unresponsive to fluid resuscitation, end organ failure, or requiring admission to ICU
2. Chronic diarrheal illness such as irritable bowel syndrome or inflammatory bowel disease unless under control or in remission of 3 months prior to enrollment
3. Taking or planning to take an investigational drug within 3 months of enrollment
4. Immunosuppression
5. Chemotherapy or radiation therapy
6. Oropharyngeal or significant esophageal dysphagia
7. Ileus or small bowel obstruction
8. Subtotal colectomy
9. Pregnancy or planning to become pregnant within 3 months of enrollment
10. Breastfeeding or planning to breastfeed during the trial
11. Active infection requiring antibiotic therapy
12. Life expectancy < 6 months

Interventions

Intervention

1 dose of 15 lyophilized fecal microbiota transplant capsules

Comparison

1 dose of 15 lyophilized sterile fecal filtrate capsules

Outcomes

Primary outcome

1. Resolution of rCDI (time frame: 8 weeks)

Secondary outcome

1. Resolution of rCDI (time frame: 24 weeks)
2. SAEs: mortality (time frame: 8 weeks)
3. SAEs: infection directly attributable to treatment (time frame: 8 weeks)

NCT03353506 (Continued)

4. Minor AEs (time frame: 1 week) nausea, vomiting, abdominal pain
5. Difficulty in swallowing capsules (time frame: 1 week)

Notes

It appears this small pilot study has been completed but there are no published data we are aware of.

NCT03548051

Methods

Multicenter, randomized, placebo-controlled, partially blinded trial

Participants

Inclusion criteria

1. Providing permission to access medical records
2. Men or non-pregnant women aged ≥ 18 years at time of enrollment
3. Able to provide signed and dated informed consent
4. ≥ 2 episodes of CDAD in past 12 months, including the last episode if present at screening (defined by ≥ 1 confirmed positive CDAD by diagnostic methods and another occurrence substantiated by medical history)
5. Completed treatment course of ≥ 10 days of oral vancomycin, oral/intravenous metronidazole, or oral fidaxomicin for the most recent episode prior to enrollment
6. Controlled diarrheal symptoms (< 3 unformed stools per 24 consecutive hour period)
7. Deemed likely to survive for 1 year after enrollment
8. Women of childbearing potential in sexual relationships with men must use an acceptable method of birth control from 30 days prior to enrollment until 4 weeks after completing study treatment
9. Men must agree to avoid impregnation of women between day 1 and day 28 following each administration of study product
10. Negative urine or serum pregnancy test within 24 hours of enrollment and randomization
11. Able to provide blood and fecal specimens
12. Able to complete a test of comprehension

Exclusion criteria

1. FMT within the previous 12 months prior to study enrollment
2. Any heart, lung, pancreas, or intestinal transplant recipient or any HIV positive-transplant recipient
3. Requiring antibiotics in past 2 weeks prior to receiving the enema for a condition other than CDAD or scheduled to be used in the upcoming 2 weeks
4. Unable to tolerate enema for any reason
5. Any GI cancer in past 6 months or any actively treated malignancy, except those actively treated for basal and squamous cell cancers without any systemic treatment
6. History of severe anaphylactic food allergy
7. People with decompensated cirrhosis, untreated HIV disease or other severe immunosuppression or immunodeficiency conditions
8. Severe or acute disease at time of enrollment
9. Major surgery of the GI tract in past 2 months
10. Non-tolerance to or any component of vancomycin, loperamide, or polyethylene glycol
11. Active inflammatory bowel disease including ulcerative colitis, Crohn disease, indeterminate colitis, or celiac disease
12. Uncontrolled irritable bowel syndrome or any active uncontrolled GI disorders or diseases
13. Unable to comply with protocol requirements.
14. Participation in any other clinical drug research trial within 30 days prior to enrollment or for 1 year after enrollment that might interfere with the safety and efficacy assessment

NCT03548051 (Continued)

15. A condition that would jeopardize the safety or rights of the person, would make it unlikely for the person to complete the study, or would confound the results of the study

Interventions	<p>Intervention</p> <p>100 g of thawed processed stool diluted into 250 mL of saline and delivered by retention enema given 1–3 hours after loperamide 4 mg orally × 1</p> <p>Comparison</p> <p>250 mL of saline delivered by retention enema given 1–3 hours after loperamide 4 mg orally × 1</p>
Outcomes	<p>Primary outcomes</p> <ol style="list-style-type: none"> 1. New-onset related chronic medical condition after completing treatment for recurrent CDAD (time frame: up to 365 days) 2. SAEs (assessed using Adverse Event Grading Scale) after completing treatment for recurrent CDAD (time frame: up to 365 days) 3. AEs (assessed using Adverse Event Grading Scale) after completing treatment for recurrent CDAD (time frame: up to 30 days) 4. Newly acquired transmissible infectious diseases that are considered Adverse Event of Special Interest, after completing treatment for recurrent CDAD (time frame: up to 365 days) 5. Clinical response (defined as no recurrence of CDAD) (time frame: up to 30 days) <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. Number of recurrences of CDAD after completing treatment for recurrent CDAD (time frame: up to 30 days and 60 days) 2. Sustained clinical response (time frame: up to 60 days) 3. Time to first CDAD recurrence (time frame: up to 60 days)
Notes	Terminated (low enrollment)

CDAD: *Clostridioides difficile*-associated diarrhea; CDI: *Clostridioides difficile* infection; EIA: enzyme immunoassay; FMT: fecal microbiota transplantation; PCR: polymerase chain reaction; rCDI: recurrent *Clostridioides difficile* infection.

Characteristics of ongoing studies [ordered by study ID]

Drekonja 2021

Study name	Microbiota or placebo after antimicrobial therapy for recurrent <i>Clostridioides difficile</i> at home: a clinical trial with novel home-based enrollment
Methods	Randomized controlled trial
Participants	Aged ≥ 18 years
Interventions	<p>Intervention: oral capsule-delivered FMT</p> <p>Control: oral capsule-delivered placebo</p>
Outcomes	<p>Primary outcomes</p> <ol style="list-style-type: none"> 1. rCDI (definite or probable) or death. Definite defined as any of the following: new onset of > 3 loose or watery stools in 24 hours for 2 consecutive days; other clinical symptoms including ileus, toxic mega colon, or colectomy; plus laboratory confirmation of <i>C difficile</i> from a stool specimen. Probable recurrence defined as the same clinical manifestations as above, but without laboratory confirmation of <i>C difficile</i> (stool test not sent, negative result, or uninterpretable result) (time frame: within 56 days of randomization)

Drekonja 2021 (Continued)

Secondary outcome

1. rCDI (definite or possible), or death (time frame: within 6 months of randomization)
2. Quality of life. Investigators will use a brief assessment of both overall and GI health status, using a previously validated instrument (time frame: 56 days from randomization)
3. Number of CDI recurrences (time frame: within 6 months of randomization)
4. Diarrhea that is negative for *C difficile* by EIA toxin test and PCR. This is similar to probable recurrent CDI, but includes only episodes of diarrhea that test negative for *C difficile* by EIA toxin test and PCR, not episodes that are not tested or are uninterpretable (time frame: within 56 days of randomization).
5. Multiple related symptoms. An assessment for non-diarrheal manifestations of CDI such as abdominal pain, urgency, and fecal incontinence will be performed (time frame: within 6 months of randomization)
6. Definite recurrent CDI. Definite recurrence defined as any of the following: new onset of > 3 loose or watery stools in 24 hours for 2 consecutive days; other clinical symptoms including ileus, toxic mega colon, or colectomy; plus laboratory confirmation of *C difficile* from a stool specimen (time frame: within 56 days of randomization)
7. Possible recurrent CDI. Defined as the same clinical manifestations as definite recurrent CDI, but without laboratory confirmation of *C difficile* (stool test not sent, negative result, or uninterpretable result) (time frame: within 56 days of randomization)
8. Death (time frame: within 56 days of randomization)
9. Diarrhea that is negative for *C difficile* by EIA toxin testing but positive by PCR. This is similar to possible recurrent CDI but includes only episodes of diarrhea that test negative for *C difficile* by EIA toxin test, not episodes that are not tested or are uninterpretable (time frame: within 56 days of randomization)

Other outcome

1. AEs and SAEs (time frame: within 6 months of randomization)

Safety outcomes

1. SAEs, with a focus on hospitalization (new or prolonged), and all-cause mortality
2. AEs that may be related to FMT treatment including AEs that investigators consider related/possibly related to the study treatment and all AEs that occur within 14 days of study treatment (since an aggregate analysis of events temporally linked to treatment could show a causal relationship when compared to placebo)
3. Infectious transmissions that are plausibly linked to FMT treatment
4. Development of new conditions theoretically linked to alterations in gut microbiota

Starting date	29 December 2016
Contact information	jane.zhang@va.gov tassos.kyriakides@va.gov
Notes	

EUCTR2015-003062-82-DK

Study name	Rectal enema with a mix of gut bacteria, rectal enema with fecal material from a healthy donor or oral given vancomycin for the treatment of patients with recurrent diarrhea caused by infection with the bacteria <i>Clostridium Difficile</i>
Methods	Randomized controlled trial (not blinded)

EUCTR2015-003062-82-DK (Continued)

Participants	Adults aged ≥ 18 years
Interventions	<p>Intervention: FMT</p> <p>Participants were pretreated with oral vancomycin 125 mg 4 times a day for 7–14 days. This was discontinued 36 hours prior to FMT. Frozen donor stool from a donor stool bank was administered by rectal enema once, but with a possibility to repeat it up to twice within 14 days after the first infusion. The indication for repetition was ongoing or new-onset diarrhea (≥ 3 loose or liquid stools per day), as judged by a trial physician, without new testing for <i>C difficile</i>. They used a different donor when repeating FMTs.</p> <p>Control 1: RBT</p> <p>The standardized laboratory-based bacterial mixture used for RBT consisted of 12 bacterial strains suspended in 200 mL isotonic saline with concentrations of 5×10^{10} bacteria of each strain. Included strains: <i>Escherichia coli</i> MT-1108-1, <i>E coli</i> MT-1109, <i>Enterococcus cassiliflavus</i>, <i>Enterococcus gallinarum</i>, <i>Bacteroides thetaiotaomicron</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides vulgatus</i>, <i>Clostridium bifermentans</i>, <i>C innocuum</i>, <i>Coprobacillus cateniformis</i>, <i>Lactobacillus rhamnosus</i>, and <i>Lactobacillus gasserii</i>. Participants were pretreated with oral vancomycin 125 mg 4 times a day for 7–14 days. This was discontinued 12 hours prior to RBT. RBT was administered by rectal enema with 3 infusions on 3 consecutive days for all participants in this group.</p> <p>Control 2: oral vancomycin</p> <p>All participants in the vancomycin group received monotherapy with oral capsule vancomycin 125 mg 4 times daily for 14 days. Furthermore, participants with ≥ 2 recurrences of CDI were treated with an additional 5 weeks of tapering as recommended in guidelines. The tapering regimen included oral vancomycin 125 mg twice daily for 1 week, 125 mg once daily for 1 week, 125 mg every other day for 1 week, and 125 mg every third day for 2 weeks.</p>
Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> 1. Clinical cure <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. 180-day mortality 2. Non-SAEs 3. SAEs
Starting date	1 May 2017
Contact information	Clinical Trial Information, Department of Medicine, Zealand University Hospital, Køge, Denmark, +45 23345235, aala@regionsjaelland.dk
Notes	

NCT02255305

Study name	FMT versus antimicrobials for initial treatment of recurrent CDI
Methods	Open-label, randomized controlled trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Diagnosis of active <i>C difficile</i> infection, defined as > 3 diarrheal stools per day and a positive <i>C difficile</i> PCR assay

NCT02255305 (Continued)

2. Hospitalized patient presenting with first relapse of CDI occurring 15–90 days after an index episode of CDI

Exclusion criteria

1. Pregnancy
2. Neutropenia (ANC < 1000/ μ L)
3. Contraindication for retention enema
4. Food allergy not controlled in the donor diet

Interventions	<p>Intervention</p> <p>50 g of fecal material given via retention enema after pretreatment with antimicrobials targeting <i>Cdifficile</i></p> <p>Comparison</p> <p>Antimicrobials targeting <i>C difficile</i></p>
Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> 1. Clinical resolution of diarrhea (time frame: 90 days) <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. Time to clinical resolution of symptoms (time frame: 6 months) 2. Hospital length of stay postprocedure (time frame: 1 week) 3. Readmission and mortality (time frame: 90 days)
Starting date	January 2015
Contact information	Becky Smith MD, Principal Investigator, NorthShore University HealthSystem
Notes	No results posted

NCT02774382

Study name	Rectal bacteriotherapy, fecal microbiota transplantation or oral vancomycin treatment of recurrent <i>Clostridium difficile</i> infections
Methods	Randomized controlled trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Age \geq 18 years 2. Verified recurrent CDI with symptoms of CDI and microbiologic verification (PCR) 3. Previously treated for CDI with \geq 10 days of vancomycin or metronidazole 4. Able to read and understand Danish <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Life expectancy < 3 months. 2. Allergy toward vancomycin 3. Other infection in the GI tract with clinical symptoms similar to CDI 4. Other illness in the GI tract with clinical symptoms similar to CDI 5. Use of antibiotics for > 14 days treating other infections 6. Planning pregnancy, pregnant, or breastfeeding.

NCT02774382 (Continued)

7. Severe immune suppression which makes FMT/RBT relatively contraindicated

Interventions	<p>Intervention</p> <p>1. Vancomycin + FMT</p> <p>Comparison</p> <p>1. Vancomycin</p> <p>2. Vancomycin + bacteriotherapy</p>
Outcomes	<p>Primary outcomes</p> <p>1. Clinical cure of rCDI defined as participant-reported absence of <i>Clostridium difficile</i> infection 90 days after treatment. The investigator will call the patient by telephone and fill out a digital questionnaire (time frame: 90 days)</p> <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. Early (first 30 days after treatment) or late (180 days after treatment) recurrence of CDI after the end of treatment defined as recurrence of symptoms of CDI and a positive stool sample with <i>C difficile</i> (PCR) (time frame: 30 and 180 days after ended treatment) 2. Days with diarrhea (time frame: 1, 4, 8 and 12 days after ended treatment) 3. CDI-associated hospital admission and hospital admission of other causes in the follow-up period (time frame: 180 days after ended treatment) 4. CDI-associated hospital outpatient contact and hospital outpatient contact of other causes in the follow-up period (time frame: 180 days after ended treatment) 5. CDI-associated mortality and all-cause mortality (time frame: 30, 90 and 180 days after ended treatment) 6. Numbers of patients with clinical cure (absence of <i>C difficile</i> infection) after study treatment divided into 2 groups depending on numbers of recurrences of CDI (time frame: 90 days after ended treatment) 7. Effect of treatment depending on the CD strain, i.e. toxin B CDI cases, toxin B plus binary toxin CDI cases and CD027 CDI cases (time frame: 90 days after ended treatment) 8. Effect of the treatment depending on the participant's serum-level of antibodies towards toxin A and B at the time of inclusion (time frame: 90 days after ended treatment) 9. Adverse effects in the 3 treatment arms (time frame: 14 days after ended treatment) 10. Characterizations of the GI microbiota before and after treatment with FMT/RBT in conjunction with characterization of the donor's microbiota or the RBT bacterial mix (time frame: 180 days after ended treatment) 11. Other antibiotic treatments associated with new recurrences of CDI (time frame: within 180 days after ended treatment) 12. Evaluation of the composition of bile acids before and after treatment with FMT/RBT (time frame: 90 days after ended treatment) 13. Characterization of the CD strains by whole genome sequencing (time frame: 90 days after ended treatment) 14. Identification of age as a risk factor for treatment success/failure (time frame: 90 days after ended treatment) 15. Identifying if Charlson comorbidity index is associated to treatment success/failure (time frame: 90 days after ended treatment)
Starting date	1 May 2017
Contact information	Andreas M Petersen MD, Principal Investigator, Hvidovre University Hospital
Notes	<p>Estimated enrollment: 450</p> <p>Status: unknown</p>

NCT03005379

Study name	Microbiota or placebo after antimicrobial therapy for recurrent <i>C. difficile</i> at home (MATCH)
Methods	Randomized clinical trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> ≥ 1 episodes recurrent CDI (defined as > 3 loose/watery stools/24 hours for 2 consecutive days with CDI treatment, and not explained by another diagnosis plus laboratory confirmation of <i>C difficile</i>; or ileus, or toxic megacolon plus laboratory confirmation of <i>C difficile</i>, occurring within 90 days of a prior CDI episode with similar symptoms and laboratory confirmation). Resolution or improvement of symptoms from most recent CDI episode, defined as no longer meeting the clinical definition for CDI for a 48-hour period during treatment, including not meeting the definition again after an initial improvement. Within the enrollment window: 2 days after completion of antimicrobial therapy for CDI (to allow for a washout period) to 14 days after completion of therapy or 30 days after the onset of CDI whichever is later. Age 18 years Enrolled in a VHA facility Able and willing to provide informed consent <p>Exclusion criteria</p> <ol style="list-style-type: none"> Unlikely to swallow capsules Pregnant, planning to be pregnant, or breastfeeding Receipt of cytotoxic chemotherapy, intravenous or subcutaneous immune globulin, or confirmed neutropenia (ANC < 1000 cells/L) within the past 3 months Inflammatory bowel disease or other chronic diarrheal disease/fecal incontinence predating CDI Ongoing antibiotic use other than those for the current episode of CDI Prior FMT Life expectancy < 8 weeks Anaphylactic food allergy Active enrollment in another research study on antibiotics, probiotics, or FMT without investigators approval Presence of an ileostomy or colostomy HIV with CD4 count < 200 cells/μL in prior 3 months Decompensated cirrhosis Bone marrow/peripheral blood stem cell transplant in the past year Unlikely to follow study protocol
Interventions	<p>Intervention</p> <p>Oral capsule-delivered FMT</p> <p>Comparison</p> <p>Oral capsule-delivered placebo</p>
Outcomes	<p>Primary outcomes</p> <p>Recurrent CDI (definite or probable) or death within 56 days of randomization. Definite recurrence defined as any of the following: new onset of > 3 loose or watery stools in 24 hours for 2 consecutive days; other clinical symptoms including ileus, toxic mega colon, or colectomy plus laboratory confirmation of <i>C difficile</i> from a stool specimen. Probable recurrence defined as the same clinical manifestations as above, but without laboratory confirmation of <i>C difficile</i> (stool test not sent, negative result, or uninterpretable result)</p>

NCT03005379 (Continued)

Secondary outcomes

1. rCDI (definite or possible), or death (time frame: within 6 months of randomization)
2. Quality of life (time frame: 56 days from randomization)
3. Number of CDI recurrences (time frame: within 6 months of randomization)
4. Diarrhea that is negative for *C difficile* by EIA toxin test and PCR (time frame: within 56 days of randomization)
5. Multiple related symptoms (non-diarrheal manifestations of CDI such as abdominal pain, urgency, and fecal incontinence) (time frame: within 6 months of randomization)
6. Definite recurrent CDI (time frame: within 56 days of randomization)
7. Possible recurrent CDI (time frame: within 56 days of randomization)
8. Death (time frame: within 56 days of randomization)
9. Diarrhea that is negative for *C difficile* by EIA toxin testing but positive by PCR (time frame: within 56 days of randomization)

Starting date	15 November 2018
Contact information	Dimitri M Drekonja MD, study chair, Minneapolis VA Health Care System, Minneapolis, Minnesota
Notes	Estimated enrollment: 390

NCT03053505

Study name	A novel faecal microbiota transplantation system for treatment of primary and recurrent <i>Clostridium difficile</i> infection (FMTREAT)
Methods	2-arm, interventional, prospective, open-label, multicenter trial
Participants	<p>Inclusion criteria</p> <p>Group "R" (non-randomized group)</p> <ol style="list-style-type: none"> 1. Recurrent CDI 2. Positive stool toxin test within 72 hours before enrollment <p>Group "F" (randomized group):</p> <ol style="list-style-type: none"> 1. First (initial) episode of CDI 2. Falls in ≥ 1 of the following categories: high risk of recurrence or high risk of developing severe CDI or severe or life-threatening CDI 3. Requires hospitalization or CDI occurs during a hospital stay 4. Persisting symptoms despite ≥ 72 hours of adequate antibiotic treatment 5. Positive stool CD toxin test obtained within 72 hours before screening <p>In all cases, primary consideration must be given to the severity and pace of the patient's CDI when deciding whether early use of FMT is appropriate to prevent further clinical deterioration.</p> <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Absence of either patient's or their legally authorized representative's informed consent 2. Inability or unwillingness to comply with protocol requirements 3. Severe comorbidities, terminal underlying disease with a life expectancy < 90 days 4. Pregnancy or breastfeeding 5. Active gastroenteritis caused by micro-organisms other than <i>C difficile</i> 6. Underlying chronic GI disease that causes diarrhea such as autonomic diabetic neuropathy, short bowel syndrome, fecal incontinence, active inflammatory bowel disease

NCT03053505 (Continued)

7. Alimentary or non-prescription drug allergy with previous anaphylactic reaction
8. Absolute contraindication to FMT

Interventions

Intervention

1. Non-randomized group ("R") for treatment of recurrent CDI with FMT

Comparison

1. Randomized group ("F" AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)
2. Randomized group ("F" FMT) for the treatment of primary CDI with FMT

Outcomes

Primary outcomes

1. Global cure rate at 10 weeks (time frame: 10 weeks after enrolment)
2. Time to clinical cure (number of days between enrolment and the resolution of diarrhea) (time frame: through study completion, a mean of 18 months)
3. Time to global cure (number of days between enrolment and the resolution of diarrhea without relapse) (time frame: through study completion, a mean of 18 months)
4. Cure rate at 2 weeks (time frame: 2 weeks after enrolment)
5. Cure rate at 4 weeks (time frame: 4 weeks after enrolment)
6. Treatment failure rate (time frame: through study completion, a mean of 18 months)
7. Recurrence rate 8 weeks after clinical cure (time frame: 8 weeks after clinical cure)

Secondary outcomes

1. Number of AEs (time frame: through study completion, a mean of 18 months)
2. Number of SAEs (time frame: through study completion, a mean of 18 months)
3. Time of hospitalization (time frame: through study completion, a mean of 18 months)
4. Days without diarrhea during study period (time frame: through study completion, a mean of 18 months)
5. Participant-related quality of life (measured with EuroQol 5Q-TL questionnaire) (time frame: 0, 7, 14 days after enrollment)
6. Professional acceptance measured using 14-item modified Treatment Satisfaction Questionnaire for Medication (time frame: through study completion, an average of 18 months)
7. General health survey for participants measured using 36-item Short Form Version 2 (time frame: 0, 7, 14 days after enrollment)
8. Patient anxiety and depression measured using the Hospital Anxiety and Depression Scale (time frame: 0, 14, 70 days after enrollment)
9. Patient acceptance of treatment measured using the 14-item modified Treatment Satisfaction Questionnaire for Medication (time frame: 14, 70 days after enrollment)

Starting date

January 2017

Contact information

Gergely G Nagy, Study Chair, University of Debrecen

Notes

No results available

NCT03806803

Study name

 Multicentre blinded comparison of lyophilized sterile fecal filtrate to lyophilized fecal microbiota transplant in recurrent *Clostridioides difficile* infection

Methods

Double-blind, randomized controlled trial

NCT03806803 (Continued)

Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> ≥ 3 episodes of recurrent CDI with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive <i>C difficile</i> test, each occurring within 3 months of each other CDI infection under symptomatic control with ≤ 3 unformed stools in 24 hours for ≥ 2 consecutive days prior to treatment Ability to provide informed consent Females and males must agree to use effective birth control for the duration of the study <p>Exclusion criteria</p> <ol style="list-style-type: none"> Severe or fulminant colitis Chronic diarrheal illnesses such as irritable bowel syndrome or inflammatory bowel disease unless under control or in remission 3 months prior to enrollment Taking or planning to take an investigational drug within 3 months of enrollment Chemotherapy or radiation therapy Oropharyngeal or significant esophageal dysphagia Ileus or small bowel obstruction Pregnant or planning to become pregnant within 3 months Breastfeeding or planning to breastfeed during the trial Active infection requiring antibiotics Life expectancy < 6 months History of total colectomy
Interventions	<p>Intervention</p> <p>Lyophilized fecal microbiota transplant capsules</p> <p>Comparison</p> <p>Lyophilized cell free fecal slurry, free of any live bacteria</p>
Outcomes	<p>Primary outcomes</p> <ol style="list-style-type: none"> Resolution of rCDI. Proportion of participants without rCDI (time frame: 8 weeks) <p>Secondary outcomes</p> <ol style="list-style-type: none"> Resolution of RCDI. Proportion of participants with sustained cure (time frame: 24 weeks) SAEs. Mortality directly attributable to CDI or treatment (time frame: 8 weeks) SAEs. Infection directly attributable to treatment (time frame: 8 weeks) Minor AEs. Nausea, vomiting, and abdominal discomfort (time frame: 1 week) Difficulty swallowing capsules. Reported by participants as ranging between none, moderate or severe (time frame: 1 week) Fever. Temperature > 37.8 °C (time frame: 1 week)
Starting date	January 2019
Contact information	Dina Kao MD, Principal Investigator, University of Alberta
Notes	No results posted

NCT03970200

Study name	PMT for severe-CDI
------------	--------------------

NCT03970200 (Continued)

Methods	Randomized, open label, comparative, phase 2 study
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> ≥ 1 episodes of CDI with symptoms including bowel movements altered in frequency or consistency from baseline Stool test positive for <i>C difficile</i> by EIA by FDA-cleared assay within 7 days prior to enrollment Age ≥ 18 years Meets any 1 of the listed criteria for severe or severe-complicated/fulminant disease within 72 hours of enrollment Receiving antibiotic treatment for S/SC/F-CDI per current Infectious Diseases Society of America guidelines <p>Exclusion criteria</p> <ol style="list-style-type: none"> Evidence of colon/small bowel perforation at the time of study screening Goals of care are directed to comfort rather than curative measures Moderate (ANC < 1000 cells/μL) or severe (ANC < 500 cells/μL) neutropenia Known food allergy that could lead to anaphylaxis Pregnancy. For people of childbearing potential (ages 18–55 years), the participant must have a negative urine pregnancy test within 48 hours of consent and ≤ 48 hours prior to first product administration. Receipt of FMT or enrollment in a clinical trial for FMT within the last 3 months COVID-19 infection, as defined by a positive nucleic acid or antigen test within the prior 14 days and symptoms consistent with COVID-19 infection
Interventions	<p>Intervention</p> <ol style="list-style-type: none"> FMT, suspension product (Penn Microbiome Therapy – 002) FMT, enema product (Penn Microbiome Therapy – 003) <p>Comparison</p> <ol style="list-style-type: none"> Antibiotics; standard of care antibiotics
Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> Resolution of symptoms after treatment with 1 of the Penn Microbiome Therapy suite of products. The outcome will be satisfied when the subject is discharged from the hospital (not to hospice or palliative care) or, while the subject remains hospitalized, when the following criteria are met for 72 hours: if radiology study or studies performed, ileus/dilation/megacolon either not noted or noted as resolved; ileus/megacolon either noted as resolved by any provider documentation or not noted; WBC < 15,000 cells/μL; serum creatinine decreased, unchanged, or increased by ≤ 0.2 mg/dL over 72 hours (if not receiving continuous renal replacement therapy or hemodialysis); lactate ≤ 2.2 mmol/L (if measured by clinical care team); no vasopressors used (including epinephrine, norepinephrine, phenylephrine, or vasopressin); temperature < 38.5 °C and ≥ 35.6 °C; < 8 bowel movements per day and < 600 mL unformed stool (if volume recorded); meeting < 3 systemic inflammatory response syndrome criteria (time frame: 7 days) <p>Secondary outcomes</p> <ol style="list-style-type: none"> Incidence of treatment-emergent AEs as assessed using CTCAE V5.0: all-cause mortality at 30- and 60-days following last FMT; colectomy or diverting ileostomy within 30 days after last FMT; cumulative days of hospitalization from enrollment until 30 days after FMT; cumulative days in ICU from enrollment until 30 days after last FMT; bacteremia from enrollment until 30 days after last FMT; repeat hospital admission within 60 days of discharge from index hospitalization Frequency SAEs assessed using CTCAE V5.0 (time frame: 180 days) Frequency of AEs of special interest assessed using CTCAE V5.0 (time frame: 180 days) Frequency solicited AEs assessed using CTCAE V5.0 (time frame: 180 days)

NCT03970200 (Continued)

Starting date	16 January 2020
Contact information	Brendan J Kelly MD, Hospital of the University of Pennsylvania
Notes	Estimated enrollment: 90 Still recruiting

NCT04885946

Study name	Fecal microbiota transplantation for early <i>Clostridioides difficile</i> infection (EarlyFMT)
Methods	Double-blind, randomized controlled trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1 or 2 CDI (within 1 year) defined as: > 3 bowel movements of Bristol 6–7 per day and positive stool CD test Age ≥ 18 years <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Pregnancy 2. Does not speak or understand the Danish language 3. Current antibiotic treatment other than vancomycin 4. Current treatment with potential interactions with vancomycin 5. Allergy to vancomycin 6. Previous anaphylactic reactions due to food allergies 7. Continuous need for proton pump inhibitor 8. Documented gastroparesis 9. Fulminant CDI
Interventions	<p>Intervention</p> <ol style="list-style-type: none"> 1. Treatment with vancomycin then single donor FMT from healthy human donors <p>Comparator</p> <ol style="list-style-type: none"> 1. Treatment with vancomycin then placebo consisting of food coloring, water, glycerol <p>Open-label for screened, but not randomized participants with fulminant CDI (considered unethical to give placebo)</p>
Outcomes	<p>Primary outcomes</p> <ol style="list-style-type: none"> 1. Resolution of CDAD. Measured as a combined clinical resolution or persistent diarrhea, but with negative CD test (time frame: 8 weeks following treatment) 2. Mortality. In the open-label arm for participants who cannot be randomized due to ethical reasons, the primary outcome is mortality (time frame: 8 weeks following treatment) <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. Resolution of CDAD. Measured as a combined clinical resolution or persistent diarrhea, but with negative CD test (time frame: 1 week following treatment) 2. Negative CD toxin. Fecal <i>C difficile</i> PCR test (time frame: 1 and 8 weeks following treatment) 3. Mortality (time frame: 8 weeks) 4. Colectomy rate. Date of colectomy (time frame: 8 weeks)

NCT04885946 (Continued)

5. Health-related quality of life measured using EQ-5D-5L (time frame: 8 weeks)

Starting date	May 2021
Contact information	Christian L Hvas PhD, Consultant, Aarhus University Hospital
Notes	No results posted

NCT04960306

Study name	Fecal filtrate as a treatment option of multiple recurrent <i>Clostridioides difficile</i> infection (FILTRATE)
Methods	Triple-blinded, randomized controlled trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> Age \geq 18 years Multiple recurrent CDI (\geq 2 previous episodes of CDI) \geq 3 loose or watery stools (Bristol 5–7) per day Positive glutamate dehydrogenase enzyme and positive CDI toxin A or B test (or both A and B) Participant or legal guardian sign the written informed consent <p>Exclusion criteria</p> <ol style="list-style-type: none"> Pregnancy or breastfeeding Ongoing antibiotic treatment Fulminant CDI Previous FMT Immunodeficiency Need of intensive care Requirement for vasoactive drugs Other cause of diarrhea Inflammatory bowel diseases Irritable bowel syndrome Life expectancy $<$ 3 months Unavailable for follow-up visits
Interventions	<p>Intervention</p> <p>5–8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size '0' capsules</p> <p>Control</p> <p>5–8 encapsulated lyophilized conventional FMTs in enterosolvent, size '0' capsules</p>
Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> Resolution of diarrhea. Clinical resolution of CDAD defined by \leq 2 stools (Bristol 1–4) per day for 2 consecutive days (time frame: 8 weeks) <p>Secondary outcomes</p> <ol style="list-style-type: none"> Resolution of diarrhea. Clinical resolution of CDAD defined by \leq 2 stools (Bristol 1–4) per day for 2 consecutive days (time frame: 1 year) Recurrence of CDI symptoms. Recurrence of the CDI symptoms (diarrhea, abdominal pain, etc.) within 8 weeks after an initial amelioration (time frame: 8 weeks, 1 year)

NCT04960306 (Continued)

3. Overall mortality (time frame: 8 weeks, 1 year)
4. Disease-associated mortality (time frame: 8 weeks, 1 year)
5. AEs and SAEs (time frame: 8 weeks, 1 year)
6. Change of the intestinal microbiome (time frame: 8 weeks, 1 year)

Starting date	July 2021
Contact information	Hegyí Péter MD, PhD, DSc, Principal Investigator, University of Pécs, Hungary
Notes	No results posted

NCT05077085

Study name	Bezlotoxumab versus FMT for multiple recurrent CDI (BSTEP)
Methods	Open-label, randomized controlled trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Age 18–90 years 2. Diarrhea (≥ 3 unformed stools per 24 hours for 2 consecutive days; or ≥ 8 unformed stools per 48 hours) 3. Positive PCR test for toxin A/B genes or positive toxin EIA for current and previous episodes (or both) (low PCR cycle threshold value when only PCR performed) 4. Minimum of 2 prior CDI episodes 5. Previous episode was maximum of 3 months prior to the current episode 6. Current episode responds well to standard of care treatment (vancomycin or fidaxomicin orally) 7. Assessment of severity of the disease will be performed according to the ESCMID recommendations 8. Both mild and severe CDI will be included <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Severe complicated CDI, i.e. presence of: hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, bowel perforation, or any fulminant course of disease 2. ICU admission for underlying disease 3. Pregnancy or current desire for pregnancy 4. Breastfeeding 5. (Prolonged) use of antibiotics (other than for treatment of CDI) during the study period or directly after the intervention 6. Previous use of bezlotoxumab or FMT 7. History of underlying congestive heart failure (potential safety signal phase-III trial bezlotoxumab) 8. Diagnosis of inflammatory bowel disease in medical history
Interventions	<p>Intervention</p> <ol style="list-style-type: none"> 1. Initial bezlotoxumab plus standard of care (14 days of vancomycin 125 mg 4 times per day plus fecal microbiota in case of treatment failure) <p>Comparator</p> <ol style="list-style-type: none"> 1. FMT plus standard of care (14 days of vancomycin 125 mg 4 times per day) plus fidaxomicin 200 mg twice daily for 10 days in case of treatment failure
Outcomes	Primary outcomes

NCT05077085 (Continued)

1. Global cure of the treatment strategy. Defined as cure without relapse of CDI within 12 weeks after completion of the treatment strategy in the study arm, i.e. after completion of secondary treatment in case of failure on initial treatment (time frame: 12 weeks (after rescue therapy if applicable))

Secondary outcomes

1. Initial cure after treatment with bezlotoxumab or FMT defined as cure after completion of the primary CDI treatment in the study arm. Initial cure assessed at day 2 after end of treatment (time frame: 2 days after end of treatment)
2. Recurrence after initial treatment with bezlotoxumab or FMT defined as CDI relapse within 12 weeks after initial cure (time frame: 12 weeks)
3. Sustained cure after initial treatment with bezlotoxumab or FMT defined as cure without relapse of CDI within 12 weeks after completion of the initial treatment (time frame: 12 weeks)
4. AEs. Throughout the entire study all AEs will be noted. After the final study procedure of the last patient, all AEs will be categorized:
 - a. most likely related to ancillary CDI treatment (bezlotoxumab or FMT)
 - b. may be related to ancillary CDI treatment
 - c. not related to ancillary CDI treatment (time frame: 12 weeks)
5. Post-treatment irritable bowel syndrome-like symptoms (time frame: 12 weeks)
6. Duration of hospitalization (time frame: 12 weeks)
7. Rate of antibiotic use (time frame: 12 weeks)
8. Eradication of toxigenic *C difficile* assessed using PCR (time frame: 3 and 12 weeks)
9. Fecal microbiota (16S) alpha- and beta-diversity assessed using 16S rRNA amplicon sequencing (time frame: pretreatment and 3 and 12 weeks)
10. Cost-effectiveness. Costs per cured participant (global and sustained cure) and costs per quality-adjusted life year gained, using the EQ-5D-5L health questionnaire that assesses 5 domains using a 5-point scale, e.g. no/slight/moderate/severe/extreme impairment and a visual analogue 0–100 scale of health rating, higher is better) (time frame: 12 weeks)

Other outcomes

1. Participant well-being. As assessed using a questionnaire, that includes:
 - a. self-rated health – 5-point scale, higher is worse outcome
 - b. happiness – 7-point scale, higher is worse outcome
 - c. optimism – 6 items
 - d. 9-item Patient Health Questionnaire – 9 items with 4-point scale, higher is worse outcome
 - e. Hospital Anxiety and Depression Scale – 14 items (time frame: pretreatment and 12 weeks)
2. Rate of participants with improved defecation pattern assessed using personal diary (time frame: 12 weeks)

Starting date	October 2021
Contact information	Joffrey van Prehn MD, PhD, Clinical Microbiologist, Leiden University Medical Center
Notes	No results posted

NCT05201079

Study name	Recurrent <i>Clostridioides difficile</i> infection treatment with capsules of lyophilised faecal microbiota vs fidaxomicin
Methods	Open-label, randomized controlled trial
Participants	Inclusion criteria

NCT05201079 (Continued)

1. Either sex aged > 18 years
2. Participants who undergo the first, second, or subsequent recurrences of CD infection, as long as they have completed ≥ 1 course of treatment with standard oral antibiotic (vancomycin) in the primary episode and which has ended ≥ 48 hours before the enrollment of the participant the study
3. Presence of an episode of diarrhea defined as ≥ 3 stools per 24 hours
4. Confirmation of the presence of CD toxin A or B (or both) in feces, by a direct toxin detection test or by the PCR technique for the detection of A or B (or both) toxin-producing genes, within 48 hours prior to the enrollment of the participant in the clinical trial

Exclusion criteria

1. Previous fecal microbiota transfer
2. Active inflammatory bowel disease (ulcerative colitis, Crohn disease, or microscopic colitis)
3. Diagnosis of irritable bowel syndrome according to Rome III criteria
4. Transplanted patients, except those with a solid organ transplant of > 2 years, with good organ function
5. ANC < 500 cells/ μ L at time of enrollment in study
6. Pregnant, breastfeeding, or pregnancy intentions over course of study
7. Active treatment with bile acid sequestrants (e.g. cholestyramine)
8. HIV-positive people except those with T lymphocytes CD4 count > 200 cells/ μ L and viral load < 20 copies
9. Active or refractory neoplasia
10. Radiation therapy in the intestinal area, previous or in progress, or active chemotherapy in last 90 days
11. Swallowing dysfunction or no oral motor co-ordination
12. Patient admitted to an ICU or expected to be admitted to an ICU due to serious illness and with indication of treatment with antibiotic

Interventions
Intervention

1. Single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally

Comparison

1. Fidaxomicin 200 mg/12 hours orally for 10 days

Outcomes
Primary outcomes

1. Global absence of diarrhea: number of episodes of diarrhea (≥ 3 stools/24 hours) 8 weeks after treatment (time frame: 8 weeks post-treatment)
2. Diarrhea resolution: < 2 stools/24 hours for ≥ 2 consecutive days after end of treatment
3. Absence of diarrhea: number of episodes of diarrhea (≥ 3 stools/24 hours) 1 and 4 weeks, 3 and 6 months after treatment

Secondary outcomes

1. Duration of hospitalization. Time, in days, that the patient remains in the hospital, from the moment the informed consent is signed until they are discharged when the diarrhea subsides (time frame: up to 8 weeks)
2. Good/bad progress of the participant. 'Bad' progress defined as the appearance of complications requiring an admission in an ICU (time frame: up to 6 months post-treatment)
3. Persistence of ≥ 2 of the following factors, after 48 hours of administered treatment: diarrhea (≥ 3 stools/24 hours) or fever (> 38 °C), or WBC > 11,000 cells/ μ L, or a combination of these
4. Time to recurrence depending on randomization groups. Defined as reappearance of clinical manifestations of a new CDI episode in a participant with an CDI episode treated and cured in the previous 8 weeks (time frame: up to 6 months post-treatment)

NCT05201079 (Continued)

5. Duration of treatment (time frame: up to 10 days)
6. Overall survival (time frame: up to 6 months post-treatment)
7. Number of AEs per randomization group (time frame: up to 6 months post-treatment)
8. Type of AEs per randomization group (time frame: up to 6 months post-treatment)
9. Number of SAEs per randomization group since baseline (time frame: up to 6 months post-treatment)
10. Type of SAEs per randomization group (time frame: up to 6 months post-treatment)
11. AEs related to the treatment since baseline (time frame: up to 6 months post-treatment)
12. AE seriousness since baseline (time frame: up to 6 months post-treatment)
13. AEs related to the CDI (time frame: up to 6 months post-treatment)
14. Mortality associated with CDI. Percentage of participants who die due to CDI after a defined period from beginning of treatment (time frame: up to 6 months post-treatment)
15. ICU admissions time. Percentage of participants admitted in the ICU after a defined period of time from beginning of treatment (time frame: up to 6 months post-treatment)
16. AEs of special interest since baseline (time frame: up to 6 months post-treatment)
17. Quality of life using 36-item Short Form. For each dimension (physical functioning, role limits-physical, bodily pain, general health, vitality, social functioning, role limits-emotional, mental health), the scale ranges from 0 (the worst health status for that dimension) to 100 (the best health status) (time frame: day 0, 8 weeks, and 6 months)

Starting date	January 2022
Contact information	Javier Cobo MD, Principal Investigator, Hospital Universitario Ramon y Cajal, Madrid, Spain
Notes	No results posted

NCT05266807

Study name	Fecal microbiota transplantation versus vancomycin or fidaxomicin in <i>Clostridioides difficile</i> infection first recurrence (FENDER)
Methods	Open-label, randomized controlled trial
Participants	<p>Inclusion criteria</p> <ol style="list-style-type: none"> 1. Adults aged ≥ 18 years at time of informed consent 2. Informed consent signature 3. Medical record documentation of first recurrence of CDI defined as: <ol style="list-style-type: none"> a. previous episode of treated and cured CDI within last 8 weeks confirmed by medical record documentation of a clinical picture of CDI combined with a CDI test performed according to CDI diagnosis ESCMID guidelines b. current combination of CDI signs and symptoms, confirmed by medical record documentation of microbiologic evidence of <i>C difficile</i> toxin and <i>C difficile</i> in stools shown by a CDI test performed according to CDI diagnosis ESCMID guidelines, with a mandatory toxin A/B EIA positive test and without reasonable evidence of another cause of diarrhea 4. No multiple episodes (> 1 recurrence) of CDI that occurred within 3 previous months 5. Already taking since < 10 days or will start a course of antibiotics (vancomycin or fidaxomicin) to control recurrent CDI symptoms at the time of screening 6. Willing and able to have FMT by capsule <p>Exclusion criteria</p> <ol style="list-style-type: none"> 1. Complicated CDI (≥ 1 of the following signs or symptoms related to CDI: hypotension requiring vasopressors, ICU admission for a complication of CDI, ileus leading to placement of nasogastric tube, toxic megacolon, colonic perforation, colectomy, or colostomy)

NCT05266807 (Continued)

2. Prior FMT within 6 months of randomization
3. Prior colectomy, colostomy, ileostomy, or gastrectomy
4. Metronidazole already given for treatment of first rCDI for > 3 days
5. Need for continued non-anti-CDI systemic antibiotics
6. Anticipated indication for antibiotics treatment (for a non-CDI reason) in next 8 weeks
7. Other infectious causes of diarrhea beyond CDI
8. Inflammatory bowel disease
9. Swallowing disorders, Zenker diverticulum, gastroparesis, or prior small bowel obstruction
10. Known hypersensitivity to vancomycin or fidaxomicin
11. Pregnant/lactating women
12. Estimated life expectancy < 10 weeks
13. Inability to follow protocol study procedures
14. Inability to give informed consent
15. Any condition or medications that will put the participant at greater risk from FMT according to the investigator
16. Severely immunocompromised

Interventions	<p>Intervention</p> <ol style="list-style-type: none"> 1. Vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per standard of care for 10 days, followed 24 hours later by 1 oral FMT (15 capsules administered at day 1 and 15 capsules at day 2), and a second oral FMT depending on recurrent CDI severity <p>Comparison</p> <ol style="list-style-type: none"> 1. Vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per standard of care for 10 days
Outcomes	<p>Primary outcome</p> <ol style="list-style-type: none"> 1. Sustained clinical cure rate. Absence of CDI recurrence (time frame: 8 weeks after study treatment completion) <p>Secondary outcomes</p> <ol style="list-style-type: none"> 1. Treatment failure: early and late CDI recurrence rate (time frame: before 4 weeks and at 5–8 weeks after study treatment completion) 2. CDI new occurrence rate (time frame: between 8 weeks and 12 months after study treatment completion) 3. Long-term clinical cure (time frame: 6 and 12 months after study treatment completion) 4. Recurrence-free survival rate from study intervention to CDI recurrence (time frame: 12 months after study treatment completion) 5. Overall survival from study intervention to death (time frame: 12 months after study treatment completion) 6. Health status EQ-5D-5L measure using 5-digit code (score from 1 to 5 for each digit, 1 representing no problem and 5 representing worse problem) (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) (time frame: baseline, 8 weeks, 6 and 12 months after study treatment completion) 7. Health status EQ-5D-5L measure using EQ visual analog scale score (0 representing the worst health you can imagine to 100 representing the best health you can imagine) (participant's perception of overall health) (time frame: baseline, 8 weeks, 6 and 12 months after study treatment completion)
Starting date	March 2022
Contact information	Benoit Guery MD, Principal Investigator, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

NCT05266807 (Continued)

Notes





































No results posted

ANC: absolute neutrophil count; CD: *Clostridioides difficile*; CDI: *Clostridioides difficile* infection; CTCAE V5.0: Common Terminology Criteria for Adverse Events Version 5.0; EIA: enzyme immunoassay; ESCMID: European Society of Clinical Microbiology and Infectious Diseases; FMT: fecal microbiota transplantation; GI: gastrointestinal; ICU: intensive care unit; PCR: polymerase chain reaction; RBT: rectal bacteriotherapy; rCDI: recurrent *Clostridioides difficile* infection; WBC: white blood cell count.



















RISK OF BIAS

Legend:  Low risk of bias  High risk of bias  Some concerns

Risk of bias for analysis 1.1 Resolution of rCDI: intention-to-treat analysis

Study	Bias					Overall
	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	
Cammarota 2015						
Hota 2017						
Hvas 2019						
Kelly 2016						
Rode 2021						
van Nood 2013						

Risk of bias for analysis 1.5 Serious adverse events: intention-to-treat analysis

Study	Bias					Overall
	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	
Cammarota 2015						
Hota 2017						
Hvas 2019						

Bias						
Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	Overall
Kelly 2016	✓	✓	✓	✓	✓	✓
Rode 2021	✓	✓	✓	✓	✓	✓
van Nood 2013	✓	✓	✓	✓	✓	✓

Risk of bias for analysis 1.7 Serious adverse events: sensitivity analysis: as-available analysis

Bias						
Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	Overall
Cammarota 2015	✓	✓	✓	✓	✓	✓
Hota 2017	⚠	✓	✓	✓	✓	✓
Hvas 2019	⚠	✓	✓	✓	✓	✓
Kelly 2016	✓	✓	✓	✓	✓	✓
Rode 2021	✓	✓	✓	✓	✓	✓
van Nood 2013	✓	✓	✓	✓	✓	✓

Risk of bias for analysis 1.9 All-cause mortality: intention-to-treat analysis

Bias						
Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	Overall
Cammarota 2015	✓	✓	✓	✓	✓	✓
Hota 2017	⚠	✓	✓	✓	✓	✓

























Bias						
Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	Overall
Hvas 2019						
Kelly 2016						
Rode 2021						
van Nood 2013						

Risk of bias for analysis 1.10 All-cause mortality: sensitivity analysis: fixed-effect model

Bias						
Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	Overall
Cammarota 2015						
Hota 2017						
Hvas 2019						
Kelly 2016						
Rode 2021						
van Nood 2013						

Risk of bias for analysis 1.12 All-cause mortality: sensitivity analysis: excluding immunocompromised participants

Bias						
Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	Overall
Cammarota 2015						

Study	Bias					Overall
	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported results	
Hota 2017						
Kelly 2016						
Rode 2021						
van Nood 2013						


DATA AND ANALYSES

Comparison 1. Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Resolution of rCDI: intention-to-treat analysis	6	320	Risk Ratio (M-H, Random, 95% CI)	1.92 [1.36, 2.71]
1.2 Resolution of rCDI: sensitivity analysis: fixed-effect model	6	320	Risk Ratio (M-H, Fixed, 95% CI)	1.92 [1.58, 2.34]
1.3 Resolution of rCDI: sensitivity analysis: as-available analysis	6	313	Risk Ratio (M-H, Random, 95% CI)	1.89 [1.31, 2.73]
1.4 Resolution of rCDI: sensitivity analysis: excluding immunocompromised participants	5	256	Risk Ratio (M-H, Random, 95% CI)	1.81 [1.23, 2.66]
1.5 Serious adverse events: intention-to-treat analysis	6	320	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.38, 1.41]
1.6 Serious adverse events: sensitivity analysis: fixed-effect model	6	320	Risk Ratio (M-H, Fixed, 95% CI)	0.64 [0.38, 1.09]
1.7 Serious adverse events: sensitivity analysis: as-available analysis	6	314	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.37, 1.38]
1.8 Serious adverse events: sensitivity analysis: excluding immunocompromised participants	5	256	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.30, 1.74]
1.9 All-cause mortality: intention-to-treat analysis	6	320	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.22, 1.45]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.10 All-cause mortality: sensitivity analysis: fixed-effect model	6	320	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.22, 1.23]
1.11 All-cause mortality: sensitivity analysis: as-available analysis	6	314	Risk Ratio (M-H, Random, 95% CI)	0.50 [0.17, 1.46]
1.12 All-cause mortality: sensitivity analysis: excluding immunocompromised participants	5	256	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.22, 1.45]
1.13 Withdrawals	6	320	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.17, 3.28]


Analysis 1.1. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 1: Resolution of rCDI: intention-to-treat analysis



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias


Analysis 1.2. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 2: Resolution of rCDI: sensitivity analysis: fixed-effect model




Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

Analysis 1.3. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 3: Resolution of rCDI: sensitivity analysis: as-available analysis




Analysis 1.4. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 4: Resolution of rCDI: sensitivity analysis: excluding immunocompromised participants



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias


Analysis 1.5. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 5: Serious adverse events: intention-to-treat analysis




Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

Analysis 1.6. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 6: Serious adverse events: sensitivity analysis: fixed-effect model




Analysis 1.7. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 7: Serious adverse events: sensitivity analysis: as-available analysis



Risk of bias legend
 (A) Bias arising from the randomization process
 (B) Bias due to deviations from intended interventions
 (C) Bias due to missing outcome data
 (D) Bias in measurement of the outcome
 (E) Bias in selection of the reported result
 (F) Overall bias


Analysis 1.8. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 8: Serious adverse events: sensitivity analysis: excluding immunocompromised participants



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias


Analysis 1.9. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 9: All-cause mortality: intention-to-treat analysis



Risk of bias legend


- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

Analysis 1.10. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 10: All-cause mortality: sensitivity analysis: fixed-effect model




Risk of bias legend
 (A) Bias arising from the randomization process
 (B) Bias due to deviations from intended interventions
 (C) Bias due to missing outcome data
 (D) Bias in measurement of the outcome
 (E) Bias in selection of the reported result
 (F) Overall bias

Analysis 1.11. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 11: All-cause mortality: sensitivity analysis: as-available analysis




Analysis 1.12. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 12: All-cause mortality: sensitivity analysis: excluding immunocompromised participants



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

Analysis 1.13. Comparison 1: Fecal microbiota transplantation (FMT) versus control for the treatment of recurrent *Clostridioides difficile* infections (rCDI), Outcome 13: Withdrawals



Risk of bias legend

- (A) Bias arising from the randomization process
- (B) Bias due to deviations from intended interventions
- (C) Bias due to missing outcome data
- (D) Bias in measurement of the outcome
- (E) Bias in selection of the reported result
- (F) Overall bias

ADDITIONAL TABLES
Table 1. List of adverse events

Adverse event	Cammarota 2015		Hota 2017		Hvas 2019		Kelly 2016		van Nood 2013		Rode 2021	
	FMT (n = 20)	Control (n = 19)	FMT (n = 16)	Control (n = 14)	FMT (n = 24)	Control (n = 40)	FMT (n = 22)	Control (n = 24)	FMT (n = 17)	Control (n = 26)	FMT (n = 34)	Control (n = 64)
Abdominal distention	—	—	9 (56%)	8 (57%)	—	—	—	—	—	—	—	—
Abdominal pain/ cramping	12 (63%)	—	10 (63%)	14 (100%)	1 (4%)	—	—	—	7 (41%)	—	11 (32%)	18 (28%)
Anasarca/edema	—	—	1 (6%)	—	—	—	—	—	—	—	—	2 (3%)
Anemia	—	—	—	—	—	—	—	—	—	—	—	1 (2%)
Anorexia	—	—	6 (38%)	5 (36%)	—	—	—	—	—	—	—	1 (2%)
Belching	—	—	—	—	—	—	—	—	3 (18%)	—	1 (3%)	1 (2%)
Bloating	12 (63%)	—	9 (56%)	13 (93%)	5 (21%)	—	—	—	—	1 (4%)	12 (35%)	16 (25%)
Bloody stools	—	—	3 (19%)	2 (14%)	—	—	—	—	—	—	—	1 (2%)
Bowel perforation	—	—	1 (6%)	—	—	—	—	—	—	—	—	—
Chest pain	—	—	—	—	—	—	—	—	—	—	—	1 (2%)
Chills	—	—	—	—	—	—	—	—	—	—	—	2 (3%)
Cholelithiasis	—	—	—	—	—	—	—	—	1 (6%)	—	—	—
Constipation	—	—	—	—	1 (4%)	—	—	—	3 (18%)	3 (12%)	—	—
Cough	—	—	—	—	—	—	—	—	—	—	1 (3%)	—
Dehydration	—	—	—	—	—	—	—	—	—	—	—	1 (2%)
Diarrhea	19 (95%)	—	10 (63%)	8 (57%)	3 (13%)	—	—	—	15 (88%)	1 (4%)	5 (15%)	15 (23%)
Dizziness	—	—	—	—	—	—	—	—	1 (6%)	—	1 (3%)	2 (3%)
Dyspepsia	—	—	—	—	—	—	—	—	—	1 (4%)	—	1 (2%)

Table 1. List of adverse events (Continued)

Dyspnea	—	—	—	—	—	—	—	—	—	—	—	2 (3%)
Epistaxis	—	—	—	—	—	—	—	—	—	—	2 (6%)	—
Fatigue	—	—	9 (56%)	13 (93%)	—	—	—	—	—	—	5 (15%)	3 (5%)
Fecal incontinence	—	—	7 (44%)	7 (50%)	—	—	—	—	—	—	1 (3%)	2 (3%)
Fever	—	—	3 (19%)	1 (7%)	—	—	—	—	1 (6%)	—	2 (6%)	4 (6%)
Flatulence	—	—	—	—	—	—	—	—	—	—	7 (21%)	3 (5%)
GI cancer diagnosed incidentally	—	—	—	—	—	—	—	1 (5%)	—	—	—	—
GI cancer recurrence	—	—	—	—	—	—	—	1 (5%)	—	—	—	—
Headache	—	—	—	—	—	—	—	—	—	—	2 (6%)	1 (2%)
Hematoma	—	—	—	—	—	—	—	—	—	—	—	1 (2%)
Hypoglycemia	—	—	—	—	—	—	—	—	—	—	—	—
Joint pain	—	—	—	—	—	—	—	1 (5%)	—	—	1 (4%)	4 (4%)
Nausea/vomiting	—	—	4 (25%)	6 (43%)	—	—	—	—	1 (6%)	—	4 (12%)	5 (8%)
Neck swelling	—	—	—	—	—	—	—	—	—	—	1 (3%)	—
Pneumonia	—	—	—	—	—	—	—	—	—	—	—	1 (2%)
Pulmonary nodule	—	—	—	—	—	—	—	1 (5%)	—	—	—	—
Rash	—	—	—	3 (21%)	—	—	—	—	—	—	1 (3%)	1 (2%)
Rectal pain with defecation	—	—	—	—	—	—	—	—	—	—	1 (3%)	1 (2%)
Seizure	—	—	—	—	—	—	—	—	—	—	1 (3%)	—
Sepsis like	—	—	—	—	1 (4%)	—	—	—	—	—	—	—

Table 1. List of adverse events (Continued)

Small bowel bacterial overgrowth	—	—	—	—	1 (4%)	—	—	—	—	—	—	—
UTI	—	—	—	1 (7%)	—	—	—	—	1 (6%)	1 (4%)	1 (3%)	—
Weight gain	—	—	—	—	—	—	1 (5%)	—	—	—	—	—

FMT: fecal microbiota transplantation; GI: gastrointestinal; UTI: urinary tract infection.

Table 2. Microbiome outcomes

Study	Methods and main findings of microbiome analysis
Hota 2017	Diversity indices were analyzed using Student t-tests interrogating the V4 hypervariable region of the 16S ribosomal RNA locus of bacterial DNA in samples from 19 donors and 3 recipients with successful outcomes. Fecal microbiota composition and diversity of the 19 donors were consistently high, with no significant difference between those associated with recipient success or failure of resolution of rCDI. Increased fecal microbiota diversity was found post-FMT in the analysis of 3 recipients who had resolution of rCDI after FMT.
Kelly 2016	<p>DNA extraction, 16S ribosomal RNA gene amplification, and sequencing were performed on donors and participants ≥ 5 days before and 2 and 8 weeks after FMT. Shannon indices and abundance-based coverage estimate parameters were calculated to assess alpha diversity, while beta diversity and abundances of genera were analyzed using analysis of similarity and Kruskal–Wallis analysis.</p> <p>All participants had marked dysbiosis prior to FMT. This persisted in those who received autologous FMT while those receiving donor FMT had a restoration of alpha diversity, a pattern seen in those who had success with rescue FMT after initial failure of treatment.</p> <p>This study had 2 sites, and analysis showed differences in the pre-FMT microbiomes between sites in both donors and recipients pre-FMT.</p>
van Nood 2013	<p>The study used paired-samples Student t-tests to examine statistical significance of a change in microbiota diversity. Wilcoxon signed-rank tests were performed to determine microbial groups in fecal samples before and after FMT infusion. The Simpson's Reciprocal Index of 9 pre-FMT patients was low (mean 57, SD 26) and increased within 2 weeks after infusion to 179, SD 42 ($P < 0.001$), which became indistinguishable from the diversity level of the donors (mean 172, SD 54). This persisted throughout the follow-up period for those who completed follow-up testing. A principal component analysis indicated a major shift in the participants' microbiota after FMT towards that of the donors. There was a statistically significant change in multiple groups of intestinal bacteria ($P < 0.05$).</p>

FMT: fecal microbiota transplantation; rCDI: recurrent *Clostridioides difficile* infections; RNA: ribonucleic acid.

APPENDICES

Appendix 1. Definitions of treatment failure, continuation of same CDI episode, rCDI, and new CDI

There is no uniformly agreed definition of treatment failure/recurrence after FMT, and studies varied with their definitions (Mullish 2018). The definition of rCDI is an episode that fulfils the criteria for CDI (both diarrheal symptoms and positive laboratory testing) and occurs between 2 and 8 weeks after treatment of a previous episode of CDI, provided that the symptoms of the earlier episode have resolved (McDonald 2007; McDonald 2018). This definition excludes any repeat positive laboratory result for *Clostridioides* within 2 weeks after the last specimen that tested positive, as this likely represents a continuation of the same CDI case (McDonald 2007). Treatment failure of CDI is defined as no response after 1 week of treatment with appropriate antibiotics (Shannon-Lowe 2010; Vardakas 2012). If the diarrhea resolves, then restarts after 8 weeks, they will be considered to have a new CDI infection (McDonald 2007; McDonald 2018).

Appendix 2. CENTRAL search strategy (via Ovid)

Search run on 16 February 2021

1. (bacteriotherap* or colonic restoration or flora reconstitution or RBX2660).tw,kw.
2. FMT.ab.
3. ((Fecal or Faecal or microbiota or microflora or feces or faeces or stool) adj3 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
4. ((bacteria or bacterio*) adj2 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
5. or/1-4

6. exp Clostridium Infections/
7. Clostridium difficile/
8. (Clostridium difficile or Clostridioides difficile or "C.difficile" or "CDAD" or "CDI" or Peptoclostridium difficile or pseudomembranous colitis).tw,kw.
9. (antibiotic* adj2 (diarrhea or diarrhoea)).tw,kw.
- 10.or/6-9
- 11.5 and 10

Search run on 31 March 2022

#1 MeSH descriptor: [Fecal Microbiota Transplantation] explode all trees

#2 (bacteriotherap* OR "colonic restoration" OR "flora reconstitution" OR RBX2660):ti,ab,kw

#3 FMT:ab

#4 ((Fecal OR Faecal OR microbiota OR microflora OR feces OR faeces OR stool) NEAR/3 (transplant* OR transfus* OR implant* OR instillation OR donor* OR enema OR reconstitution OR infusion* OR therap* OR transfer* OR treat*)):ti,ab,kw

#5 ((bacteria OR bacterio*) NEAR/2 (transplant* OR transfus* OR implant* OR instillation OR donor* OR enema OR reconstitution OR infusion* OR therap* OR transfer* OR treat*)):ti,ab,kw

#6 #1 OR #2 OR #3 OR #4 OR #5

#7 MeSH descriptor: [Clostridium Infections] explode all trees

#8 MeSH descriptor: [Clostridioides difficile] explode all trees

#9 ("Clostridium difficile" OR "Clostridioides difficile" OR "C.difficile" OR CDAD OR CDI OR "Peptoclostridium difficile" OR "pseudomembranous colitis"):ti,ab,kw

#10 (antibiotic* NEAR/2 (diarrhea or diarrhoea)):ti,ab,kw

#11 #7 OR #8 OR #9 OR #10

#12 #6 AND #11

Custom date range: 16 February 2021 to 31 March 2022

Appendix 3. MEDLINE (via Ovid)

Search run on 16 February 2021

1. Fecal Microbiota Transplantation/
2. (bacteriotherap* or colonic restoration or flora reconstitution or RBX2660).tw,kw.
3. FMT.ab.
4. ((Fecal or Faecal or microbiota or microflora or feces or faeces or stool) adj3 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
5. ((bacteria or bacterio*) adj2 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
6. or/1-5
7. exp Clostridium Infections/
8. Clostridium difficile/
9. (Clostridium difficile or Clostridioides difficile or "C.difficile" or "CDAD" or "CDI" or Peptoclostridium difficile or pseudomembranous colitis).tw,kw.
- 10.(antibiotic* adj2 (diarrhea or diarrhoea)).tw,kw.
- 11.or/7-10
- 12.6 and 11
- 13.randomized controlled trial.pt.
- 14.controlled clinical trial.pt.
- 15.random*.ab.
- 16.placebo.ab.

17.trial.ab.
18.groups.ab.
19.drug therapy.fs.
20.or/13-19
21.exp animals/ not humans.sh.
22.20 not 21
23.12 and 22

Note: lines 13-22 Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid format. Minor revision was made: randomised.ab. and randomly.ab. was replaced by "random*.ab" to capture terms such as randomized, randomization.

Search run on 31 March 2022

1 exp Fecal Microbiota Transplantation/
2 (bacteriotherap* or colonic restoration or flora reconstitution or RBX2660).tw,kw.
3 FMT.ab.
4 ((Fecal or Faecal or microbiota or microflora or feces or faeces or stool) adj3 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
5 ((bacteria or bacterio*) adj2 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
6 or/1-5
7 exp Clostridium Infections/
8 exp Clostridioides difficile/
9 (Clostridium difficile or Clostridioides difficile or "C.difficile" or "CDAD" or "CDI" or Peptoclostridium difficile or pseudomembranous colitis).tw,kw.
10 (antibiotic* adj2 (diarrhea or diarrhoea)).tw,kw.
11 or/7-10
12 6 and 11
13 randomized controlled trial.pt.
14 controlled clinical trial.pt.
15 random*.mp.
16 placebo.ab.
17 trial.ab.
18 groups.ab.
19 drug therapy.fs.
20 or/13-19
21 exp animals/ not humans.sh.
22 20 not 21
23 12 and 22
24 limit 23 to dt=20210216-20220331

Appendix 4. Embase (via Ovid)

Search run on 16 February 2021

1. fecal microbiota transplantation/
2. feces microflora/ and exp therapy/
3. (bacteriotherap* or colonic restoration or flora reconstitution or RBX2660).tw,kw.
4. FMT.ab.
5. ((Fecal or Faecal or microbiota or microflora or feces or faeces or stool) adj3 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
6. ((bacteria or bacterio*) adj2 (transplant* or transfus* or implant* or instillation or donor* or enema or reconstitution or infusion* or therap* or transfer* or treat*)).tw,kw.
7. or/1-6
8. Clostridium difficile infection/ or clostridioides difficile/
9. pseudomembranous colitis/
- 10.(Clostridium difficile or Clostridioides difficile or "C.difficile" or "CDAD" or "CDI" or Peptoclostridium difficile or pseudomembranous colitis).tw,kw.
- 11.(antibiotic* adj2 (diarrhea or diarrhoea)).tw,kw.
- 12.or/8-11
- 13.7 and 12
- 14.random:.tw.
- 15.placebo:.mp.
- 16.double-blind:.tw.
- 17.or/14-16
- 18.exp animal/ not human/
- 19.17 not 18
- 20.13 and 19

Note: Line 14-17. Hedge Best balance of sensitivity and specificity filter for identifying "therapy studies" in Embase. hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx

Search run on 31 March 2022

- #25 #24 AND [16-02-2021]/sd NOT [31-03-2022]/sd
- #24 #15 AND #23
- #23 #19 NOT #22
- #22 #20 NOT #21
- #21 'human'/exp
- #20 'animal'/exp
- #19 #16 OR #17 OR #18
- #18 'double blind':ti,ab
- #17 placebo
- #16 random*:ti,ab
- #15 #9 AND #14
- #14 #10 OR #11 OR #12 OR #13
- #13 (antibiotic* NEAR/2 (diarrhea OR diarrhoea)):ti,ab,kw
- #12 'clostridium difficile':ti,ab,kw OR 'clostridioides difficile':ti,ab,kw OR 'c.difficile':ti,ab,kw OR 'cdad':ti,ab,kw OR 'cdi':ti,ab,kw OR 'peptoclostridium difficile':ti,ab,kw OR 'pseudomembranous colitis':ti,ab,kw

#11 'clostridioides difficile'/exp

#10 'clostridium difficile infection'/exp

#9 #1 OR #4 OR #5 OR #6 OR #7 OR #8

#8 ((bacteria OR bacterio*) NEAR/2 (transplant* OR transfus* OR implant* OR instillation OR donor* OR enema OR reconstitution OR infusion* OR therap* OR transfer* OR treat*)):ti,ab,kw

#7 ((fecal OR faecal OR microbiota OR microflora OR feces OR faeces OR stool) NEAR/3 (transplant* OR transfus* OR implant* OR instillation OR donor* OR enema OR reconstitution OR infusion* OR therap* OR transfer* OR treat*)):ti,ab,kw

#6 fmt:ab

#5 bacteriotherap*:ti,ab,kw OR 'colonic restoration':ti,ab,kw OR 'flora reconstitution':ti,ab,kw OR rbx2660:ti,ab,kw

#4 #2 AND #3

#3 'therapy'/exp

#2 'feces microflora'/exp

#1 'fecal microbiota transplantation'/exp

Appendix 5. Conference Proceedings Citation Index and ISRCTN

Search strategy run on 31 March 2022

Conference Proceedings Citation Index

9 #5 AND #8

8 #6 OR #7

7 TS=((antibiotic* NEAR/2 (diarrhea OR diarrhoea)))

6 TS=("Clostridium difficile" OR "Clostridioides difficile" OR "C.difficile" OR CDAD OR CDI OR "Peptoclostridium difficile" OR "pseudomembranous colitis")

5 #1 OR #2 OR #3 OR #4

4 TS=(((bacteria OR bacterio*) NEAR/2 (transplant* OR transfus* OR implant* OR instillation OR donor* OR enema OR reconstitution OR infusion* OR therap* OR transfer* OR treat*)))

3 TS=(((Fecal OR Faecal OR microbiota OR microflora OR feces OR faeces OR stool) NEAR/3 (transplant* OR transfus* OR implant* OR instillation OR donor* OR enema OR reconstitution OR infusion* OR therap* OR transfer* OR treat*)))

2 AB=(FMT)

1 TS=(bacteriotherap* OR "colonic restoration" OR "flora reconstitution" OR RBX2660)

ISRCTN

("fecal transplant" OR "faecal transplant" OR "stool transplant" OR "stool therapy" OR "fecal microbial transplant" OR "fecal microbiota transplant" OR "fecal microbiota transplantation" OR "faecal microbiota transplant" OR "faecal microbiota transplantation" OR FMT OR bacteriotherapy OR "colonic restoration" OR "flora reconstitution" OR RBX2660) AND ("Clostridium difficile" OR "Clostridioides difficile" OR "C.difficile" OR CDAD OR CDI OR "Peptoclostridium difficile" OR "pseudomembranous colitis")

HISTORY

Protocol first published: Issue 2, 2021

CONTRIBUTIONS OF AUTHORS

The contributions of authors based on tasks of the review are as follows.

Conception of the review: AI

Design of the review: NZM, AI, MN, SA, JPZ, ETS

Co-ordination of the review: AI, NZM

Search and selection of studies for inclusion in the review: SHA, MM, NZM, AI

Collection of data for the review: SHA, MM, AI

Assessment of the risk of bias in the included studies: SHA, MM, AI

Analysis of data: SHA, MM, AI

Assessment of the certainty in the body of evidence: AI

Interpretation of data: AI, MN, SA, ETS, JPZ, NZM

Writing of the review: NZM, AI

All the authors reviewed and agreed to the manuscript before submission. AI is the guarantor of the review.

DECLARATIONS OF INTEREST

NZM: none.

AI: none.

SA: none.

MM: none.

ETS: none.

JZ: Dr Zackular's research laboratory receives research funding from BioNTech, but Dr Zackular does not receive any compensation for this work.

SA: none.

MN: National Institute of Allergy and Infectious Diseases K23 award [No. 1K23AI156132-01] to MRN. Dr Nicholson serves on a data and safety monitoring board for Summit Therapeutics.

SOURCES OF SUPPORT

Internal sources

- None, Other

None

External sources

- National Institute of Allergy and Infectious Diseases K23 award (No.1K23AI156132-01), USA

Dr. Maribeth Nicholson is supported by a grant from NIH

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We made the following changes from our protocol ([Imdad 2021](#)).

1. We had planned to compare "stool bank" versus "non-stool bank" storage of FMT. These titles were changed to "fresh stool (of non-stool bank origin)" versus "frozen then thawed stool (of stool bank origin)" to be more specific regarding the storage/handling of the stool. This subgroup analysis was not conducted due to the low number of included studies.
2. Individuals with inflammatory bowel disease (IBD) experience CDI at a higher rate than the general population, have a higher rate of rCDI, are often on immunosuppressive medication, and show a less robust increase in gut microbial diversity after FMT than people without IBD ([Khanna 2017](#); [Razik 2016](#)). For these reasons, we had planned to exclude participants with IBD from our analysis, however, as only [Hvas 2019](#) explicitly stated that it included people with IBD, and they were less than 25% of those in the study, we decided not to exclude this study, to maximize the total number of participants in our study rather than exclude a study based on a small number of participants with IBD. To assess whether this could have impacted our results significantly we completed sensitivity analyses on all

outcomes in the summary of findings table excluding the [Hvas 2019](#) study, none of which found the exclusion of this study to impact the outcomes significantly.

3. The data on 'treatment failure' and 'new CDI after successful treatment' could not be distinguished from 'recurrence of CDI', so these outcomes were not available from the included studies. We expected differences between included studies in the definitions of treatment efficacy, treatment failure, and what they defined as rCDI as opposed to a new case of CDI after a previously successful FMT. We planned to standardize the definitions of treatment failure, rCDI, and new CDI across all studies as per the definitions in [Appendix 1](#). However, we found no papers that used these definitions nor were we able to apply these time-bound definitions to the raw data from the included studies based on the way the studies themselves reported the results. We used the definition of efficacy as defined by the included studies, as long as it encompassed a resolution of symptoms after treatment, as we planned a priori.
4. We planned to assess the risk of bias for the outcomes of treatment failure, colectomy, and mortality; however, data were only available for mortality. We additionally assessed the risk of bias for serious adverse events and resolution of rCDI.
5. We initially planned to use a fixed-effect model to synthesize data; however, we decided to use the random-effects model to adjust for any heterogeneity across the studies. We completed sensitivity analyses to determine if this impacted the outcomes reported in the summary of findings table significantly; this showed minimal impact.
6. We had planned a sensitivity analysis comparing studies with a high risk of bias versus those with low risk of bias/some concerns; however, there were no studies at high risk of bias.
7. We did not conduct any of the planned subgroup analysis as the number of included studies was fewer than 10 and it is very unlikely that an investigation of heterogeneity will produce useful findings unless there are at least 10 studies in a meta-analysis.

INDEX TERMS

Medical Subject Headings (MeSH)

Anti-Bacterial Agents [therapeutic use]; Clostridioides; *Clostridioides difficile; *Clostridium Infections [drug therapy] [microbiology]; Dysbiosis; Fecal Microbiota Transplantation [adverse effects]; Quality of Life; Recurrence; Treatment Outcome

MeSH check words

Adult; Child; Humans